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directed to epitopes of Human Immunodeficiency Virus, or 
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HIV antibodies used for prophylaxis, and methods for diag 
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HUMAN IMMUNODEFICIENCY VIRUS 
NEUTRALIZING ANTIBODIES AND 
METHODS OF USE THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
0001. This application is a U.S. National Phase of Inter 
national Application No. PCT/US2012/038400, filed May 
17, 2012, which claims priority under 35 U.S.C. S 119(e) to 
U.S. Provisional Application No. 61/486,960 filed on May 
17, 2011. The disclosures of which are hereby incorporated in 
their entirety. 
STATEMENT REGARDING FEDERALLY 
FUNDED RESEARCH 
0002 The research leading to the present invention was 
supported in part, by National Institutes of Health Grant No. 
P01 AI08677-01. Accordingly, the U.S. Government has cer 
tain rights in this invention. 
FIELD OF THE INVENTION 
0003. The present invention relates to antibodies directed 
to epitopes of Human Immunodeficiency Virus (“HIV). The 
present invention further relates to the preparation and use of 
broadly neutralizing antibodies directed to the HIV gp120 
envelope protein for the prevention and treatment of HIV 
infection. 
BACKGROUND OF THE INVENTION 
0004 HIV causes Acquired Immunodeficiency Syndrome 
(AIDS”). The immune response to HIV infection in long 
term non-progressors suggests that specific viral immunity 
may limit infection and the symptoms of disease. Some HIV 
infected individuals show broadly neutralizing IgG antibod 
ies in their serum; little is known regarding the specificity and 
activity of these antibodies, despite their potential importance 
in designing effective vaccines, and no single characteristic 
has of yet been correlated with protective immunity. In animal 
models, passive transfer of neutralizing antibodies can con 
tribute to protection against virus challenge. Neutralizing 
antibody responses also can be developed in HIV-infected 
individuals but the detailed composition of the serologic 
response is yet to be fully uncovered. 
0005. A number of immunologic abnormalities have been 
described in AIDS. These include, but are not limited to, 
abnormalities in B-cell function, abnormal antibody 
response, defective monocyte cell function, impaired cytok 
ine production, depressed natural killer and cytotoxic cell 
function, defective ability of lymphocytes to recognize and 
respond to soluble antigens, and the depletion of the T4 
helper/inducer lymphocyte population. 
0006. The amino acid and RNA sequences encoding HIV 
env from a number of HIV strains are known (Modrow, S. et 
al., J. Virology 61(2): 570 (1987)). The HIV virion is covered 
by a membrane or envelope derived from the outer membrane 
of host cells. This membrane contains a population of enve 
lope glycoproteins (gp 160) anchored in the membrane 
bilayer at their carboxyl terminal region. Each glycoprotein 
contains two segments: the N-terminal segment, and the 
C-terminal segment. The N-terminal segment, called gp120 
by virtue of its relative molecular weight of about 120 kD. 
protrudes into the aqueous environment Surrounding the 
virion. The C-terminal segment, called gp41, spans the mem 
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brane. The N-terminal gp120 and the C-terminal gp41 are 
covalently linked by a peptide bond that is particularly sus 
ceptible to proteolytic cleavage. See European Patent Appli 
cation Publication No. 0 335 635 to McCune et all and the 
references cited therein, each incorporated herein by refer 
ence in its entirety. 
0007. Several approaches to an AIDS vaccine have been 
proposed, including, but not limited to, inactivated and 
attenuated virus vaccines, Subunit vaccines from virus-in 
fected cells, recombinantly produced viral antigens, vaccines 
based on synthetic peptides, anti-idiotypic vaccines, and viral 
carrier-based vaccines. An additional approach to HIV thera 
peutic and prophylactic treatment includes making highly 
potent, broadly neutralizing monoclonal antibodies. Multiple 
studies have reported cloning and making monoclonal anti 
bodies by various techniques for targeting the CD4 binding 
site as well as other parts of the virion spike and for neutral 
izing HIV. Generally, these techniques involve self-fusion or 
phage display techniques. Typically, in making HIV neutral 
izing antibodies using phage display techniques, random 
combinations of heavy and light chains are combined and a 
random pair is selected. Studies have reported a limited num 
ber of monoclonal antibodies, such as, for example, the phage 
display antibody b12, that are broadly highly potent, and 
broadly neutralizing (meaning antibodies that can neutralize 
multiple strains of HIV in sera) against HIV. The monoclonal 
antibody b12 is a broadly neutralizing antibody which has 
been reported to prevent HIV infection in macaques. Another 
broadly neutralizing antibody includes 2G12, which, atypi 
cally, has a structure which has yet to be seen in any other 
antibody with three combining sites. VRCO1 is recently dis 
covered broadly neutralizing antibody that targets the CD4 
binding site (CD4bs) on the HIV spike. VRC01 was isolated 
by purifying single B cells that bind to a soluble, biotin 
labeled, stabilized, and re-surfaced core fragment of HIV 
gp120 (X. Wu et al., Science 329, 856 (Aug. 13, 2010)). 
Although Successful, the isolation was inefficient, producing 
only 3 closely related HIV-binding antibodies from 25 mil 
lion peripheral blood mononuclear cells from one individual. 
Like other anti-HIV antibodies obtained by the single cell 
antigen capture method, VRC01-3 showed very high levels of 
Somatic mutations that were essential for potency and 
breadth. This high frequency of mutation is a potential 
impediment to antibody cloning because the mutated 
sequences may no longer be complementary to the primers 
used for cloning. 
0008. Some studies have reported that certain patients 
develop antibodies to HIV that are broadly neutralizing. Stud 
ies have reported that antibodies can be protective against 
initial HIV infection in passive transfer experiments in non 
human primates and can modulate viral load during infection. 
See, for example, Mascola, 2000; Shibata, 1999; Veazey, 
2003; Parren, 2001; Mascola, 1999; Trkola, 2005: Wei, 2003: 
Frost, 2005; Burton, 2004; Mascola, 2007; Karlsson Hedes 
tam, 2008; McMichael, 2006; Zola-Pazner, 2004. 
BRIEF SUMMARY OF THE INVENTION 
0009. The present invention, in one embodiment, provides 
broadly neutralizing antibodies against HIV. In one embodi 
ment, the present invention provides an isolated HIV anti 
body comprising a heavy chain comprising the consensus 
amino acid sequence: QXXLXQSGGXVKKPGXSVX 
VSCXASGYXXFXXYXIHWXRQAPGXGXXWVGXI 
XPRXGXXXXAXXFQGRLSLTRDXXXXXX 
US 2014/0328862 A1 
TXXXFMDLXGLRXDDTAVYFCARX 
XXXXXXXXXXXXXXXXXDX (SEQ ID NO: 1) wherein 
X indicates any amino acid or no amino acid. 
0010. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a light chain com 
prising the consensus amino sequence: EIXLTQSPXSLSX 
SXGEXXTISCXXXQXXXXXXXLXWYQQRXGXARPL 
LIXXXSX XXXGVPXRFSGXXXGXXYXLXISXLXXD 
DXAXYFCXXYEXXXXXXX (SEQ ID NO:2) wherein X 
indicates any amino acid or no amino acid. 
0011. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a heavy chain 
comprising a highly conserved consensus sequence and a 
light chain comprising a highly conserved consensus 
sequence. The present invention further provides a method of 
producing an isolated HIV antibody comprising a heavy 
chain comprising a highly conserved consensus sequence and 
a light chain comprising a highly conserved consensus 
Sequence. 
0012. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising the heavy chain 
consensus sequence of SEQ ID NO:1 and the light chain 
sequence of SEQ ID NO:2. In a further embodiment, the 
present invention provides an isolated HIV antibody compris 
ing one or both of the heavy chain consensus sequence of 
SEQID NO:1 and the light chain sequence of SEQID NO:2, 
or sequences having at least 70%, or at least 80%, or at least 
85%, or at least 90%, or at least 95%, or at least 97%, or at 
least 98%, or at least 99% identity thereto, with the proviso 
that the antibody does not have the amino acid sequence of 
VRCO1. 
0013. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising one or both of the 
heavy chain consensus sequence of SEQ ID NO:1 and the 
light chain consensus sequence of SEQID NO:2 and wherein 
the antibody neutralizes HIV virus ZM53M.PB12 at an ICso 
concentration of less than 1.0 ug/ml, or HIV virus R1166.c1 
at an ICso concentration of less than 1.0 ug/ml, or DU172.17 
at an ICso concentration of less than 30 ug/ml. In another 
embodiment, the present invention provides an isolated HIV 
antibody comprising one or both of the heavy chain consen 
sus sequence of SEQID NO:1 and the light chain consensus 
sequence of SEQID NO:2, wherein the antibody neutralizes 
a VRCO1-resistant HIV virus at an ICs concentration of less 
than 30 g/ml. 
0014. In another embodiment, the present invention pro 
vides an isolated HIV antibody selected from the group con 
sisting of 3BNC117, 3BNC60, 12A12, 12A21, NIH45-46, 
8ANC 131, 8ANC134, IB2530, INC9 and 8ANC 196. 
0015. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising heavy chain 
CDR1, CDR2 and CDR3 regions and light chain CDR1, 
CDR2 and CDR3 regions comprising the amino acid 
sequences of the corresponding regions of an HIV antibody 
selected from the group consisting of 3BNC117, 3BNC60, 
12A12, 12A21, NIH45-46, b ANC 131, 8ANC134, IB2530, 
INC9 and 8ANC 196. 
0016. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a heavy chain 
comprising an amino acid sequence selected from the group 
consisting of SEQID NOs: 5-438. 
0017. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a light chain com 
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prising an amino acid sequence selected from the group con 
sisting of SEQID NOs: 439-583. 
0018. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a heavy chain and 
a light chain comprising an amino acid sequence set forth in 
Table A or Table B. 
0019. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising an insertion 
sequence comprising the amino acid sequence: ASWDFDF 
(SEQID NO:3). 
0020. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising an insertion 
sequence comprising the amino acid sequence: TARDY 
(SEQID NO:4). 
0021. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising insertion 
sequences SEQID No. 3 and SEQID No. 4. 
0022. In another embodiment, the present invention pro 
vides a method to improve the HIV neutralization potency 
and breadth of an isolated HIV antibody comprising inserting 
at least one of insertion sequences SEQID No. 3 and SEQID 
No. 4. 
0023. According to another embodiment, the present 
invention provides compositions comprising an isolated HIV 
antibody of the invention. 
0024. According to another embodiment, the present 
invention provides pharmaceutical compositions comprising 
an antibody of the invention and a pharmaceutically accept 
able carrier. 
0025. According to another embodiment, the present 
invention provides nucleic acid molecules encoding an iso 
lated HIV antibody of the invention. 
0026. According to other embodiments, the present inven 
tion provides vectors comprising nucleic acid molecules 
encoding an isolated HIV antibody of the invention, and cells 
comprising Such vectors. 
0027. According to another embodiment, the present 
invention provides a method of preventing or treating HIV 
infection or an HIV-related disease comprising the steps of: 
identifying a mammalian Subject in need of Such prevention 
or treatment, and administering to said Subject a therapeuti 
cally effective amount of at least one HIV antibody of the 
invention. 
0028. According to another embodiment, the method fur 
ther comprises the administration of a second therapeutic 
agent. According to another embodiment, the second thera 
peutic agent is an antiviral agent. 
0029. Another embodiment of the present invention pro 
vides a method of reducing virus replication or spread of 
infection to additional host cells or tissues comprising con 
tacting a mammalian cell with at least one antibody of the 
invention. According to another aspect, the present invention 
provides for a method for treating a mammalian Subject 
infected with HIV, the method comprising administering to 
said subject a pharmaceutical composition comprising at 
least one antibody according to the invention. 
0030. According to another embodiment, the present 
invention provides a method for the preparation and admin 
istration of an HIV antibody preparation which is suitable for 
administration to a mammalian Subject having or at risk of 
HIV infection, in an amount and according to a schedule 
Sufficient to induce a protective immune response against 
HIV or reduction of the HIV virus in a mammalian subject. In 
another embodiment, the present invention provides a method 
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for detecting an HIV antibody comprising a heavy chain 
comprising a highly conserved consensus sequence and a 
light chain comprising a highly conserved consensus 
sequence in a biological sample. 
0031. In another embodiment, the present invention pro 
vides the isolated antibodies of the invention for use in the 
treatment of HIV. 
0032. In another embodiment, the present invention pro 
vides a kit comprising a pharmaceutically acceptable dose 
unit of a pharmaceutically effective amount of at isolated HIV 
antibody of the invention, and a pharmaceutically acceptable 
dose unit of a pharmaceutically effective amount of an HIV 
agent selected from the group consisting of a non-nucleoside 
reverse transcriptase inhibitor, a protease inhibitor, a entry or 
fusion inhibitor and an integrase inhibitors, wherein the two 
pharmaceutically acceptable dose units can optionally take 
the form of a single pharmaceutically acceptable dose unit. 
0033. In another embodiment, the present invention pro 
vides a kit for the diagnosis, prognosis or monitoring the 
treatment of HIV in a Subject comprising one or more detec 
tion reagents which specifically bind to anti-HIV neutralizing 
antibodies in a biological sample from a subject. In another 
aspect of the invention, the kit further provides reagents for 
performing PCR or mass spectrometry. 
BRIEF DESCRIPTION OF THE DRAWINGS 
0034 FIGS. 1A-D show the HIV antibody neutralizing 
activity ICso. (A) Limited panel. Top line indicates the donor 
number, then clone or antibody (Table 4); viruses are shown 
on the left. Colors indicate concentration at ICs: reds0.1 
ug/ml, orange 0.1-1 g/ml, yellow 1-10 g/ml, greens 10 
ug/ml, white not neutralized at any concentration tested. (B) 
Extended panel. (C) Neutralization Summary graph compar 
ing VRC01, NIH45-46,3BNC117. Length of lines and size of 
circles inversely proportional to ICso. Colors indicate viral 
clades: red A: blue B; green C: fucia D; black AE; gold AG. 
(D) Sequence of 3BNC60, 1B2530 and 8ANC134 heavy 
chains with coverage by peptides found by Mass Spec in light 
grey. Red dots indicate differences from respective germline 
Sequences. 
0035 FIGS. 2A-C show the binding properties of the HIV 
antibodies. (A) Representive SPR sensograms for binding to 
YU2-gp140 and 2CC-core by 12A12, 12A21 and 12A-ger 
mline (GL) reverted antibodies. (B) Graph shows K for 
representative antibodies. (C) Graph shows mean fluores 
cence intensity of anti-CD4i antibody binding to Ba1.26 
expressing 293T cells after incubation with the indicated 
antibodies. Table indicates whether or not an antibody 
induces CD4i site accessibility. 
0036 FIGS. 3A and B show the HIV antibody consensus 
sequence, and HIV antibody amino acid sequences. (A) 
Amino acid alignment relative to framework (FR) and CDR 
regions for consensus, germline genes, 10 selected antibodies 
and 8ANC 195. Residues are numbered according to the 
3BNC60 structure. (B) As in (A) for light chains. (C, D, and 
E) Crystal structure of 3BNC60 Fab. 
0037 FIGS. 4A and B show recovery of highly mutated 
immunoglobulin heavy chains with specific primers. (A) side 
by side comparison of new and old primer set. Red boxes 
indicate successful amplification of IgV genes. (B) HIV 
antibodies that bind to 2CC-core from Pt 8. Clonal families 
are shown by differently expanded slices. Two highly mutated 
clones that were not amplified with the old primer set are 
shown in Striped pie slices. 
Nov. 6, 2014 
0038 FIG. 5 shows IgV heavy (A) and light chain (B) 
sequences of new VRC01 clonal members. 
0039 FIG. 6 shows patient serum neutralizing activity. 
(A) Table Summarizes purified serum IgG neutralizing activ 
ity against a panel of Tier 2 viruses in a TZm-b1 assay. Dark 
red boxes indicate ICs values below 10 g/ml, orange 
between 10 and 100 g/ml and yellow above 100 ug/ml. (B) 
dot plot Summarizes the ICso values shown in A for the 4 more 
extensively tested patients. 
0040 FIG.7 demonstrates detection of antibodies by mass 
spectrometry. Collision activated dissociation MS/MS spec 
trum recorded on the doubly charged peptides HSDYCDFD 
VWGSGSQVIVSSASTK from 3BNC153HC(A) and DGL 
GEVAPAYLYGIDAWGQGTTVIVTSASTK from 
8ANC134HC. (B. Observed b-type fragment ions (contain 
ing the N-terminus) and y-type fragmentions (containing the 
C-terminus) are labeled in the spectrum. Loss of water from 
fragmentions is indicated by *. Ions corresponding to the loss 
of water from the parent ion are labeled in the spectrum. 
Observed backbone cleavages are indicated in the sequence 
with for b-type ions and for y type ions. 
004.1 FIGS. 8A and B demonstrate affinity of HIV anti 
bodies. (A) Antibody binding to gp140 and 2CC-core mea 
sured by surface plasmon resonance (SPR). The SPR sen 
sograms for antibody binding of the selected 3BNC-antibody 
clones are shown over time. (B) Bar graphs show the binding 
affinity (K) for gp140 and 2CC-core antigens for the 
selected IgG antibodies shown in A. RU, response units. 
0042 FIGS. 9A-C illustrate the somatic hypermutation 
analysis of selected HIV antibodies for (A) immunoglobulin 
heavy chain gene, (B) light chain kappa and (C) light chain 
lambda gene sequences. Sequences are aligned with their 
respective germline nucleotide sequences. Somatic muta 
tions are shown in red letters, additionally gray boxes desig 
nate replacement mutations. Germline amino acid sequences 
with * indicating consensus residues are shown above the 
nucleotide alignment. 
0043 FIGS. 10 A-C shows antibody sequences from one 
expanded neutralizing clone in each (A) Patient (Pt)1, (B) Pt3 
and (C) Pt8. Peptides identified by mass spectrometry are 
indicated in color. The variants marked with an asterisk are 
uniquely defined by one or more mass spectrometrically 
observed peptides (shown in lightgrey). The remaining mass 
spectrometrically observed peptides map non-uniquely to 
multiple variants as shown in dark grey. Underlined amino 
acids indicate non-tryptic cleavage sites in the variants 
shown. The cleavages are presumed to occurthrough chymot 
ryptic cleavage or additional mutations (not observed among 
the cloned variants) that place a lysine or arginine residue at 
these sites. 
DETAILED DESCRIPTION OF THE INVENTION 
I. HIV Neutralizing Antibodies 
0044) The present invention, in one embodiment, provides 
broadly neutralizing antibodies against HIV. In one embodi 
ment, the present invention provides an isolated HIV anti 
body comprising a heavy chain comprising the consensus 
amino acid sequence: QXXLXQSGGXVKKPGXSVX 
VSCXASGYXXFXXYXIHWXRQAPGXGXXWVGXI 
XPRXGXXXXAXXFQGRLSLTRDXXXXXX 
TXXXFMDLXGLRXDDTAVYFCARX 
XXXXXXXXXXXXXXXXXDX (SEQ ID NO: 1) wherein 
X indicates any amino acid or no amino acid. 
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0045. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a light chain com 
prising the consensus amino sequence: EIXLTQSPXSLSX 
SXGEXXTISCXXXQXXXXXXXLXWYQQRXGXARPL 
LIXXXSX XXXGVPXRFSGXXXGXXYXLXISXLXXD 
DXAXYFCXXYEXXXXXXX (SEQ ID NO:2) wherein X 
indicates any amino acid or no amino acid. 
0046. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising the heavy chain 
sequence of SEQ ID NO:1 and the light chain sequence of 
SEQID NO:2. In a further embodiment, the present invention 
provides an isolated HIV antibody comprising one or both of 
the heavy chain sequence of SEQID NO:1 and the light chain 
sequence of SEQID NO:2, or sequences having at least 70%, 
or at least 80%, or at least 85%, or at least 90%, or at least 
95%, or at least 97%, or at least 98%, or at least 99% identity 
thereto, with the proviso that the antibody does not have the 
amino acid sequence of VRC01. Percentage identity is deter 
mined as disclosed hereinbelow. 
0047. The present invention provides, in other embodi 
ments, an isolated HIV antibody comprising a heavy chain 
comprising an highly conserved heavy chain amino acid 
sequence and a light chain comprising a highly conserved 
light chain amino acid sequence. A highly conserved heavy 
chain amino acid sequence is defined herein as an amino acid 
sequence having at least 70%, or at least 80%, or at least 85%, 
or at least 90%, or at least 95%, or at least 97%, or at least 
98%, or at least 99% identity with the sequence of SEQ ID 
NO:1. A highly conserved light chain amino acid sequence is 
defined hereinas an amino acid sequence having at least 70%, 
or at least 80%, or at least 85%, or at least 90%, or at least 
95%, or at least 97%, or at least 98%, or at least 99% identity 
with the sequence of SEQ ID NO:2. Percentage identity is 
determined as disclosed hereinbelow. 
0048. In another embodiment, present invention provides 
an isolated HIV antibody comprising a heavy chain compris 
ing an highly conserved heavy chainamino acid sequence and 
a light chain comprising a highly conserved light chain amino 
acid sequence, with the proviso that the antibody does not 
have the sequence of VRC01. 
0049. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising one or both of the 
heavy chain sequence of SEQID NO:1 and the light chain 
sequence of SEQID NO:2 and wherein the antibody neutral 
izes HIV virus ZM53M.PB12 at an ICso concentration of less 
than 1.0 g/ml, or HIV virus R1166.c1 at an ICso concentra 
tion of less than 1.0 g/ml, or DU172.17 at an ICs concen 
tration of less than 30 g/ml. In another embodiment, the 
present invention provides an isolated HIV antibody compris 
ing one or both of the heavy chain sequence of SEQID NO:1 
and the light chain sequence of SEQ ID NO:2, wherein the 
antibody neutralizes a VRC01-resistant HIV virus at an ICso 
concentration of less than 30 ug/ml. AVRC01-resistant HIV 
virus is defined herein as an HIV virus that is resistant to 
neutralization by VRC01 at an ICs value of 50 g/ml. 
VRC01-resistant HIV viruses include, for example, HO86.8, 
DU172.17, 250-4, 278-50, and 620345.c1. 
0050. In another embodiment, the present invention pro 
vides an isolated HIV antibody selected from the group con 
sisting of 3BNC117, 3BNC60, 12A12, 12A21, NIH45-46, 
bANC131, 8ANC134, IB2530, INC9 and 8ANC 196. 
0051. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising heavy chain 
CDR1, CDR2 and CDR3 regions and light chain CDR1, 
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CDR2 and CDR3 regions comprising the amino acids 
sequences of the corresponding regions of an HIV antibody 
selected from the group consisting of 3BNC117, 3BNC60, 
12A12, 12A21, NIH45-46, b ANC 131, 8ANC134, IB2530, 
INC9 and 8ANC 196. 
0052. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a heavy chain 
comprising an amino acid sequence selected from the group 
consisting of SEQID NOs: 5-438. 
0053. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a light chain com 
prising an amino acid sequence selected from the group con 
sisting of SEQID NOs: 439-583. 
0054. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising a heavy chain and 
a light chain comprising an amino acid sequence set forth in 
Table A or Table B. 
0055. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising an insertion 
sequence comprising the amino acid sequence: ASWDFDF 
(SEQID NO:3). In a further embodiment, the present inven 
tion provides an isolated HIV antibody wherein insertion 
sequence SEQID No. 3, which corresponds to the FR3 region 
of the heavy chain commencing at amino acid 74 of 
3BNC 117 and 3BNC60 as shown in FIG. 5A, is substituted 
for the corresponding region, as determined by sequence 
alignment, of an HIV antibody of the invention. For example, 
SEQID No. 3 may be inserted after the seventhamino acid of 
FR3 of the heavy chain. 
0056. In another embodiment, the present invention pro 
vides an isolated HIV antibody comprising an insertion 
sequence comprising the amino acid sequence: TARDY 
(SEQID NO:4). In a further embodiment, the present inven 
tion provides an isolated HIV antibody wherein insertion 
sequence SEQ ID No. 4, which corresponds to the CDR3 
region of the heavy chain commencing at amino acid 103 of 
NIH45-46 as shown in FIG. 5A, is substituted for the corre 
sponding region, as determined by sequence alignment, of an 
HIV antibody of the invention. For example, SEQID No. 4 
may be inserted after the fourth amino acid of CDR3 of the 
heavy chain. 
0057. In another embodiment, the present invention pro 
vides an isolated HIV antibody wherein insertion sequence 
SEQ ID No. 3, which corresponds to the FR3 region of the 
heavy chain commencing at amino acid 74 of 3BNC 117 and 
3BNC60 as shown in FIG. 5A, is substituted for the corre 
sponding region, as determined by sequence alignment, of an 
HIV antibody of the invention, and insertion sequence SEQ 
ID No. 4, which corresponds to the CDR3 region of the heavy 
chain commencing at amino acid 103 of NIH45-46 as shown 
in FIG. 5A, is substituted for the corresponding region, as 
determined by sequence alignment, of an HIV antibody of the 
invention. For example, SEQID No. 3 may be inserted after 
the seventhamino acid of FR3 of the heavy chain and SEQID 
No. 4 may be inserted after the fourth amino acid of CDR3 of 
the heavy chain. 
0058. In a further embodiment, the present invention pro 
vides a method to improve the HIV neutralization potency 
and breadth of an isolated HIV antibody comprising making 
an isolated HIV antibody wherein insertion sequence SEQID 
No. 3, which corresponds to the FR3 region of the heavy 
commencing at amino acid 74 of 3BNC117 and 3BNC60 as 
shown in FIG.5A, is substituted for the corresponding region, 
as determined by sequence alignment, of an HIV antibody of 
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the invention and/or the insertion sequence SEQ ID No. 4, 
which corresponds to the CDR3 region of the heavy chain 
commencing at amino acid 103 of NIH45-46 as shown in 
FIG.5A, is substituted for the corresponding region, as deter 
mined by sequence alignment, of an HIV antibody of the 
invention. For example, SEQID No. 3 may be inserted after 
the seventhamino acid of FR3 of the heavy chain, and/or SEQ 
ID No. 4 may be inserted after the fourth amino acid of CDR3 
of the heavy chain. One skilled in this art can modify the 
amino acid sequence of an antibody utilizing recombinant 
methods and/or synthetic chemistry techniques for the pro 
duction of a polypeptide or an antibody. Also, one skilled in 
the art can identify an improved HIV antibody with greater 
neutralization potency and breadth by using a HIV neutral 
ization assay, as described below. 
0059. In another embodiment, the present invention pro 
vides an improved isolated HIV antibody comprising at least 
one of insertion sequences SEQIDNO:3 and SEQID NO:4, 
wherein the improved isolated HIV antibody has greater HIV 
neutralization potency and breadth, than said isolated HIV 
antibody without insertion sequences SEQID NO:3 and SEQ 
ID NO: 4. One skilled in the art can identify the improved 
HIV antibody with greater HIV neutralization potency and 
breadth by using the HIV neutralization assay, as described 
below. 
0060. One skilled in this art can modify the amino acid 
sequence of an antibody utilizing recombinant methods and/ 
or synthetic chemistry techniques for the production of a 
polypeptide or an antibody. 
0061. In another embodiment, the present invention pro 
vides for a method to make an isolated HIV antibody com 
prising the heavy chain consensus sequence of SEQID NO:1 
and the light chain sequence of SEQ ID NO:2. In a further 
embodiment, the present invention provides for a method of 
producing an isolated HIV antibody comprising one or both 
of the heavy chain consensus sequence of SEQID NO:1 and 
the light chain sequence of SEQ ID NO:2, or sequences 
having at least 70%, or at least 80%, or at least 85%, or at least 
90%, or at least 95%, or at least 97%, or at least 98%, or at 
least 99% identity thereto, with the proviso that the antibody 
does not have the amino acid sequence of VRC01. Percentage 
identity is determined as disclosed hereinbelow. 
0062. In another embodiment, the present invention pro 
vides a method for detecting an isolated HIV antibody com 
prising obtaining an immunoglobulin-containing biological 
sample from a mammalian Subject, isolating an HIV antibody 
from said sample, determining the amino sequence of the 
HIV antibody and identifying the presence of the heavy chain 
sequence of SEQ ID NO:1 and the light chain sequence of 
SEQID NO:2. In a further embodiment, the present invention 
provides for a method of selecting an isolated HIV antibody 
comprising determining the presence of one or both of the 
heavy chain consensus sequence of SEQ ID NO:1 and the 
light chain sequence of SEQID NO:2, or sequences having at 
least 70%, or at least 80%, or at least 85%, or at least 90%, or 
at least 95%, or at least 97%, or at least 98%, or at least 99% 
identity thereto, with the proviso that the antibody does not 
have the amino acid sequence of VRC01. Percentage identity 
is determined as disclosed herein below. The biological 
sample may be blood, serum, saliva, urine, sputum, a cell 
Swab Sample, or a tissue biopsy. The amino acid sequences 
may be determined by methods known in the art including, for 
example, PCR and mass spectrometry. 
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0063. The term “antibody’ (Ab) as used herein includes 
monoclonal antibodies, polyclonal antibodies, multispecific 
antibodies (for example, bispecific antibodies and polyreac 
tive antibodies), and antibody fragments. Thus, the term 
“antibody' as used in any context within this specification is 
meant to include, but not be limited to, any specific binding 
member, immunoglobulin class and/or isotype (e.g., IgG1. 
IgG2, IgG3, IgG4, IgM, IgA, Ig|D, IgE and IgM); and bio 
logically relevant fragment or specific binding member 
thereof, including but not limited to Fab, F(ab')2, Fv, and schv 
(single chain or related entity). It is understood in the art that 
an antibody is a glycoprotein comprising at least two heavy 
(H) chains and two light (L) chains inter-connected by disul 
fide bonds, or an antigen binding portion thereof. A heavy 
chain is comprised of a heavy chain variable region (VH) and 
a heavy chain constant region (CH1, CH2 and CH3). A light 
chain is comprised of a light chain variable region (VL) and a 
light chain constant region (CL). The variable regions of both 
the heavy and light chains comprise framework regions 
(FWR) and complementarity determining regions (CDR). 
The four FWR regions are relatively conserved while CDR 
regions (CDR1, CDR2 and CDR3) represent hypervariable 
regions and are arranged from NH2 terminus to the COOH 
terminus as follows: FWR1, CDR1, FWR2, CDR2, FWR3, 
CDR3, FWR4. The variable regions of the heavy and light 
chains containabinding domain that interacts with an antigen 
while, depending of the isotype, the constant region(s) may 
mediate the binding of the immunoglobulin to host tissues or 
factors. 
0064. Also included in the definition of “antibody” as used 
herein are chimeric antibodies, humanized antibodies, and 
recombinant antibodies, human antibodies generated from a 
transgenic non-human animal, as well as antibodies selected 
from libraries using enrichment technologies available to the 
artisan. 
0065. The term “variable' refers to the fact that certain 
segments of the variable (V) domains differ extensively in 
sequence among antibodies. The V domain mediates antigen 
binding and defines specificity of a particular antibody for its 
particular antigen. However, the variability is not evenly dis 
tributed across the 110-amino acid span of the variable 
regions. Instead, the V regions consist of relatively invariant 
stretches called framework regions (FRs) of 15-30 amino 
acids separated by shorter regions of extreme variability 
called “hypervariable regions' that are each 9-12 amino acids 
long. The variable regions of native heavy and light chains 
each comprise four FRS, largely adopting a beta sheet con 
figuration, connected by three hyperVariable regions, which 
form loops connecting, and in Some cases forming part of the 
beta sheet structure. The hypervariable regions in each chain 
are held together in close proximity by the FRs and, with the 
hypervariable regions from the other chain, contribute to the 
formation of the antigen-binding site of antibodies (see, for 
example, Kabat et al., Sequences of Proteins of Immunologi 
cal Interest, 5th Ed. Public Health Service, National Institutes 
of Health, Bethesda, Md. (1991)). 
0066. The term “hypervariable region” as used herein 
refers to the amino acid residues of an antibody that are 
responsible for antigen binding. The hyperVariable region 
generally comprises amino acid residues from a "comple 
mentarity determining region” (“CDR). 
0067. The term “monoclonal antibody” as used herein 
refers to an antibody obtained from a population of Substan 
tially homogeneous antibodies, i.e., the individual antibodies 
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comprising the population are identical except for possible 
naturally occurring mutations that may be present in minor 
amounts. The term “polyclonal antibody' refers to prepara 
tions that include different antibodies directed against differ 
ent determinants (“epitopes'). 
0068. The monoclonal antibodies herein include “chi 
meric' antibodies in which a portion of the heavy and/or light 
chain is identical with, or homologous to, corresponding 
sequences in antibodies derived from a particular species or 
belonging to a particular antibody class or Subclass, while the 
remainder of the chain(s) is identical with, or homologous to, 
corresponding sequences in antibodies derived from another 
species or belonging to another antibody class or Subclass, as 
well as fragments of such antibodies, so long as they exhibit 
the desired biological activity (see, for example, U.S. Pat. No. 
4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 
81:6851-6855 (1984)). The described invention provides 
variable region antigen-binding sequences derived from 
human antibodies. Accordingly, chimeric antibodies of pri 
mary interest herein include antibodies having one or more 
human antigen binding sequences (for example, CDRS) and 
containing one or more sequences derived from a non-human 
antibody, for example, an FR or C region sequence. In addi 
tion, chimeric antibodies included herein are those compris 
ing a human variable region antigenbinding sequence of one 
antibody class or subclass and another sequence, for example, 
FR or C region sequence, derived from anotherantibody class 
or Subclass. 
0069. A “humanized antibody” generally is considered to 
be a human antibody that has one or more amino acid residues 
introduced into it from a source that is non-human. These 
non-human amino acid residues often are referred to as 
“import residues, which typically are taken from an 
“import' variable region. Humanization may be performed 
following the method of Winter and co-workers (see, for 
example, Jones et al., Nature, 321:522-525 (1986); Reich 
mann et al., Nature, 332:323-327 (1988); Verhoeyen et al., 
Science, 239:1534-1536 (1988)), by substituting import 
hyperVariable region sequences for the corresponding 
sequences of a human antibody. Accordingly, such "human 
ized antibodies are chimeric antibodies (see, for example, 
U.S. Pat. No. 4,816,567), wherein substantially less than an 
intact human variable region has been substituted by the 
corresponding sequence from a non-human species. 
0070 An “antibody fragment comprises a portion of an 
intact antibody. Such as the antigenbinding or variable region 
of the intact antibody. Examples of antibody fragments 
include, but are not limited to, Fab, Fab'. F(ab')2, and Fv 
fragments; diabodies; linear antibodies (see, for example, 
U.S. Pat. No. 5,641,870; Zapata et al., Protein Eng. 8(10): 
1057-1062 1995); single-chain antibody molecules; and 
multispecific antibodies formed from antibody fragments. 
0071 "Fv is the minimum antibody fragment that con 
tains a complete antigen-recognition and antigen-binding 
site. This fragment contains a dimer of one heavy- and one 
light-chain variable region domain in tight, non-covalent 
association. From the folding of these two domains emanate 
six hypervariable loops (three loops each from the H and L 
chain) that contribute the amino acid residues for antigen 
binding and confer antigen binding specificity to the anti 
body. However, even a single variable region (or half of an Fv 
comprising only three CDRS specific for an antigen) has the 
ability to recognize and bind antigen, although at a lower 
affinity than the entire binding site. 
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(0072 "Single-chain Fv' (“sev” or “scFv’) are antibody 
fragments that comprise the VH and VL antibody domains 
connected into a single polypeptide chain. The SFV polypep 
tide can further comprise a polypeptide linker between the 
VH and VL domains that enables the sRv to form the desired 
structure for antigen binding. For a review of slfv, see, for 
example, Pluckthun in The Pharmacology of Monoclonal 
Antibodies, vol. 113, Rosenburg and Moore eds., Springer 
Verlag, New York, pp. 269-315 (1994); Borrebaeck 1995, 
infra. 
(0073. The term “diabodies” refers to small antibody frag 
ments prepared by constructing SEV fragments with short 
linkers (about 5-10 residues) between the VH and VL 
domains such that inter-chain but not intra-chain pairing of 
the V domains is achieved, resulting in a bivalent fragment, 
i.e., fragment having two antigen-binding sites. Bispecific 
diabodies are heterodimers of two “crossover sRV fragments 
in which the VH and VL domains of the two antibodies are 
present on different polypeptide chains. Diabodies are 
described more fully in, for example, EP 404,097; WO 
93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 
90:6444-6448 (1993). 
0074 Domain antibodies (dAbs), which can be produced 
in fully human form, are the Smallest known antigen-binding 
fragments of antibodies, ranging from about 11 kDa to about 
15 kDa. dAbs are the robust variable regions of the heavy and 
light chains of immunoglobulins (VH and VL, respectively). 
They are highly expressed in microbial cell culture, show 
favorable biophysical properties including, for example, but 
not limited to, solubility and temperature stability, and are 
well suited to selection and affinity maturation by in vitro 
selection systems such as, for example, phage display. dAbs 
are bioactive as monomers and, owing to their Small size and 
inherent stability, can be formatted into larger molecules to 
create drugs with prolonged serum half-lives or other phar 
macological activities. Examples of this technology have 
been described in, for example, WO942.5591 for antibodies 
derived from Camelidae heavy chain Ig, as well in 
US2003.0130496 describing the isolation of single domain 
fully human antibodies from phage libraries. 
0075 Fv and slfv are the only species with intact combin 
ing sites that are devoid of constant regions. Thus, they are 
Suitable for reduced nonspecific binding during in vivo use. 
sEv fusion proteins can be constructed to yield fusion of an 
effector protein at either the amino or the carboxy terminus of 
an SFv. See, for example, Antibody Engineering, ed. Borre 
baeck, Supra. The antibody fragment also can be a "linear 
antibody', for example, as described in U.S. Pat. No. 5,641, 
870 for example. Such linear antibody fragments can be 
monospecific or bispecific. 
0076. In certain embodiments, antibodies of the described 
invention are bispecific or multi-specific. Bispecific antibod 
ies are antibodies that have binding specificities for at least 
two different epitopes. Exemplary bispecific antibodies can 
bind to two different epitopes of a single antigen. Other such 
antibodies can combine a first antigen binding site with a 
binding site for a second antigen. Alternatively, an anti-HIV 
arm can be combined with an arm that binds to a triggering 
molecule on a leukocyte. Such as a T-cell receptor molecule 
(for example, CD3), or Fc receptors for IgG (Fc gamma R), 
such as Fc gamma RI (CD64), Fc gamma RII (CD32) and Fc 
gamma RIII (CD16), so as to focus and localize cellular 
defense mechanisms to the infected cell. Bispecific antibod 
ies also can be used to localize cytotoxic agents to infected 
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cells. Bispecific antibodies can be prepared as full length 
antibodies orantibody fragments (for example, F(ab')2 bispe 
cific antibodies). For example, WO 96/16673 describes a 
bispecific anti-ErbB2/anti-Fc gamma RIII antibody and U.S. 
Pat. No. 5,837,234 discloses a bispecific anti-ErbB2/anti-Fc 
gamma RI antibody. For example, a bispecific anti-ErbB2/Fc 
alpha antibody is reported in WO98/02463: U.S. Pat. No. 
5,821.337 teaches a bispecific anti-ErbB2/anti-CD3 anti 
body. See also, for example, Mouquet et al., Polyreactivity 
Increases The Apparent Affinity Of Anti-HIV Antibodies. By 
Heteroligation. NATURE. 467, 591-5 (2010). 
0077 Methods for making bispecific antibodies are 
known in the art. Traditional production of full length bispe 
cific antibodies is based on the co-expression of two immu 
noglobulin heavy chain-light chain pairs, where the two 
chains have different specificities (see, for example, Millstein 
et al., Nature, 305:537-539 (1983)). Similar procedures are 
disclosed in, for example, WO 93/08829, Traunecker et al., 
EMBO.J., 10:3655-3659 (1991) and see also: Mouquet et al., 
Polyreactivity Increases The Apparent Affinity Of Anti-HIV 
Antibodies By Heteroligation. NATURE. 467,591-5 (2010). 
0078. Alternatively, antibody variable regions with the 
desired binding specificities (antibody-antigen combining 
sites) are fused to immunoglobulin constant domain 
sequences. The fusion is with an Ig heavy chain constant 
domain, comprising at least part of the hinge, CH2, and CH3 
regions. According to Some embodiments, the first heavy 
chain constant region (CH1) containing the site necessary for 
light chain bonding, is present in at least one of the fusions. 
DNAS encoding the immunoglobulin heavy chain fusions 
and, if desired, the immunoglobulin light chain, are inserted 
into separate expression vectors, and are co-transfected into a 
suitable host cell. This provides for greater flexibility in 
adjusting the mutual proportions of the three polypeptide 
fragments in embodiments when unequal ratios of the three 
polypeptide chains used in the construction provide the opti 
mum yield of the desired bispecific antibody. It is, however, 
possible to insert the coding sequences for two or all three 
polypeptide chains into a single expression vector when the 
expression of at least two polypeptide chains in equal ratios 
results in high yields or when the ratios have no significant 
affect on the yield of the desired chain combination. 
007.9 Techniques for generating bispecific antibodies 
from antibody fragments also have been described in the 
literature. For example, bispecific antibodies can be prepared 
using chemical linkage. For example, Brennan et al., Science, 
229: 81 (1985) describe a procedure wherein intactantibodies 
are proteolytically cleaved to generate F(ab')2 fragments. 
These fragments are reduced in the presence of the dithiol 
complexing agent, sodium arsenite, to stabilize vicinal dithi 
ols and prevent intermolecular disulfide formation. The Fab' 
fragments generated then are converted to thionitrobenzoate 
(TNB) derivatives. One of the Fab'-TNB derivatives then is 
reconverted to the Fab'-thiol by reduction with mercaptoet 
hylamine and is mixed with an equimolar amount of the other 
Fab'-TNB derivative to form the bispecific antibody. The 
bispecific antibodies produced can be used as agents for the 
selective immobilization of enzymes. 
0080. Other modifications of the antibody are contem 
plated herein. For example, the antibody can be linked to one 
of a variety of nonproteinaceous polymers, for example, poly 
ethylene glycol, polypropylene glycol, polyoxyalkylenes, or 
copolymers of polyethylene glycol and polypropylene gly 
col. The antibody also can be entrapped in microcapsules 
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prepared, for example, by coacervation techniques or by 
interfacial polymerization (for example, hydroxymethylcel 
lulose or gelatin-microcapsules and poly-(methylmethacy 
late)microcapsules, respectively), in colloidal drug delivery 
systems (for example, liposomes, albumin microspheres, 
microemulsions, nano-particles and nanocapsules), or in 
macroemulsions. Such techniques are disclosed in, for 
example, Remington’s Pharmaceutical Sciences, 16th edi 
tion, Oslo, A., Ed., (1980). 
I0081 Typically, the antibodies of the described invention 
are produced recombinantly, using vectors and methods 
available in the art. Human antibodies also can be generated 
by in vitro activated B cells (see, for example, U.S. Pat. Nos. 
5,567,610 and 5,229.275). General methods in molecular 
genetics and genetic engineering useful in the present inven 
tion are described in the current editions of Molecular Clon 
ing: A Laboratory Manual (Sambrook, et al., 1989, Cold 
Spring Harbor Laboratory Press), Gene Expression Technol 
ogy (Methods in Enzymology, Vol. 185, edited by D. Goed 
del, 1991. Academic Press, San Diego, Calif.), “Guide to 
Protein Purification' in Methods in Enzymology (M. P. 
Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: 
A Guide to Methods and Applications (Innis, et al. 1990. 
Academic Press, San Diego, Calif.), Culture of Animal Cells: 
A Manual of Basic Technique, 2nd Ed. (R.I. Freshney. 1987. 
Liss, Inc. New York, N.Y.), and Gene Transfer and Expression 
Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press 
Inc., Clifton, N.J.). Reagents, cloning vectors, and kits for 
genetic manipulation are available from commercial vendors 
Such as BioRad, Stratagene, Invitrogen, ClonTech and 
Sigma-Aldrich Co. 
I0082 Human antibodies also can be produced in trans 
genic animals (for example, mice) that are capable of produc 
ing a full repertoire of human antibodies in the absence of 
endogenous immunoglobulin production. For example, it has 
been described that the homozygous deletion of the antibody 
heavy-chain joining region (JH) gene in chimeric and germ 
line mutant mice results in complete inhibition of endogenous 
antibody production. Transfer of the human germ-line immu 
noglobulin gene array into Such germ-line mutant mice 
results in the production of human antibodies upon antigen 
challenge. See, for example, Jakobovits et al., Proc. Natl. 
Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 
362:255-258 (1993); Bruggemann et al., Year in Immuno. 
7:33 (1993); U.S. Pat. Nos. 5,545,806, 5,569,825, 5,591,669 
(all of GenPharm): U.S. Pat. No. 5,545,807; and WO 
97/17852. Such animals can be genetically engineered to 
produce human antibodies comprising a polypeptide of the 
described invention. 
I0083 Various techniques have been developed for the pro 
duction of antibody fragments. Traditionally, these fragments 
were derived via proteolytic digestion of intact antibodies 
(see, for example, Morimoto et al., Journal of Biochemical 
and Biophysical Methods 24:107-117 (1992); and Brennanet 
al., Science, 229:81 (1985)). However, these fragments can 
now be produced directly by recombinant host cells. Fab, Fv 
and ScHv antibody fragments can all be expressed in and 
secreted from E. coli, thus allowing the facile production of 
large amounts of these fragments. Fab'-SH fragments can be 
directly recovered from E. coli and chemically coupled to 
form F(ab')2 fragments (see, for example, Carter et al., Bio/ 
Technology 10:163-167 (1992)). According to another 
approach, F(ab')2 fragments can be isolated directly from 
recombinant host cell culture. Fab and F(ab')2 fragment with 
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increased in Vivo half-life comprising a salvage receptor 
binding epitope residues are described in U.S. Pat. No. 5,869, 
046. Other techniques for the production of antibody frag 
ments will be apparent to the skilled practitioner. 
0084. Other techniques that are known in the art for the 
selection of antibody fragments from libraries using enrich 
ment technologies, including but not limited to phage display, 
ribosome display (Hanes and Pluckthun, 1997, Proc. Nat. 
Acad. Sci. 94: 4937-4942), bacterial display (Georgiou, et al., 
1997, Nature Biotechnology 15:29-34) and/or yeast display 
(Kieke, et al., 1997, Protein Engineering 10: 1303-1310) may 
be utilized as alternatives to previously discussed technolo 
gies to select single chain antibodies. Single-chain antibodies 
are selected from a library of single chain antibodies pro 
duced directly utilizing filamentous phage technology. Phage 
display technology is known in the art (e.g., see technology 
from Cambridge Antibody Technology (CAT)) as disclosed 
in U.S. Pat. Nos. 5,565,332; 5,733,743; 5,871,907; 5,872, 
215; 5,885,793; 5,962.255; 6,140,471; 6,225,447; 6,291650: 
6,492,160; 6,521,404: 6,544,731; 6,555,313; 6,582,915; 
6.593,081, as well as other U.S. family members, or applica 
tions which rely on priority filing GB9206318, filed 24 May 
1992; see also Vaughn, et al. 1996, Nature Biotechnology 14: 
309-314). Single chain antibodies may also be designed and 
constructed using available recombinant DNA technology, 
such as a DNA amplification method (e.g., PCR), or possibly 
by using a respective hybridoma cDNA as a template. 
0085 Variant antibodies also are included within the 
scope of the invention. Thus, variants of the sequences recited 
in the application also are included within the scope of the 
invention. Further variants of the antibody sequences having 
improved affinity can be obtained using methods known in 
the art and are included within the scope of the invention. For 
example, amino acid Substitutions can be used to obtain anti 
bodies with further improved affinity. Alternatively, codon 
optimization of the nucleotide sequence can be used to 
improve the efficiency of translation in expression systems 
for the production of the antibody. 
I0086 Such variant antibody sequences will share 70% or 
more (i.e., 80%, 85%, 90%. 95%,97%.98%, 99% or greater) 
sequence identity with the sequences recited in the applica 
tion. Such sequence identity is calculated with regard to the 
full length of the reference sequence (i.e., the sequence 
recited in the application). Percentage identity, as referred to 
herein, is as determined using BLAST version 2.1.3 using the 
default parameters specified by the NCBI (the National Cen 
ter for Biotechnology Information: http://www.ncbi.nlm.nih. 
gov/) Blosum 62 matrix; gap open penalty=11 and gap 
extension penalty=1). For example, peptide sequences are 
provided by this invention that comprise at least about 5, 10, 
15, 20, 30, 40, 50, 75, 100, 150, or more contiguous peptides 
of one or more of the sequences disclosed hereinas well as all 
intermediate lengths there between. As used herein, the term 
“intermediate lengths' is meant to describe any length 
between the quoted values, such as 7, 8, 9, 10, 11, 12, 13, 14. 
15, 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 
52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151,152, 153, etc. 
0087. The present invention provides for antibodies, either 
alone or in combination with otherantibodies, such as, but not 
limited to, VRC01 and PG9, that have broad neutralizing 
activity in serum. 
0088 According to another embodiment, the present 
invention provides methods for the preparation and adminis 
tration of an HIV antibody composition that is suitable for 
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administration to a human or non-human primate patient 
having HIV infection, or at risk of HIV infection, in an 
amount and according to a schedule Sufficient to induce a 
protective immune response against HIV, or reduction of the 
HIV virus, in a human. 
I0089. According to another embodiment, the present 
invention provides a vaccine comprising at least one antibody 
of the invention and a pharmaceutically acceptable carrier. 
According to one embodiment, the vaccine is a vaccine com 
prising at least one antibody described herein and a pharma 
ceutically acceptable carrier. The vaccine can include a plu 
rality of the antibodies having the characteristics described 
herein in any combination and can further include antibodies 
neutralizing to HIV as are known in the art. 
0090. It is to be understood that compositions can be a 
single or a combination of antibodies disclosed herein, which 
can be the same or different, in order to prophylactically or 
therapeutically treat the progression of various Subtypes of 
HIV infection after vaccination. Such combinations can be 
selected according to the desired immunity. When an anti 
body is administered to an animal or a human, it can be 
combined with one or more pharmaceutically acceptable car 
riers, excipients or adjuvants as are known to one of ordinary 
skilled in the art. The composition can further include broadly 
neutralizing antibodies known in the art, including but not 
limited to, VRCO1, PG9 and b12. 
0091. Further, with respect to determining the effective 
level in a patient for treatment of HIV, in particular, suitable 
animal models are available and have been widely imple 
mented for evaluating the in vivo efficacy against HIV of 
various gene therapy protocols (Sarver et al. (1993b), supra). 
These models include mice, monkeys and cats. Even though 
these animals are not naturally susceptible to HIV disease, 
chimeric mice models (for example, SCID, bg/nu/xid, NOD/ 
SCID, SCID-hu, immunocompetent SCID-hu, bone marrow 
ablated BALB/c) reconstituted with human peripheral blood 
mononuclear cells (PBMCs), lymph nodes, fetal liver/thymus 
or other tissues can be infected with lentiviral vector or HIV, 
and employed as models for HIV pathogenesis. Similarly, the 
simian immune deficiency virus (SIV)/monkey model can be 
employed, as can the feline immune deficiency virus (FIV)/ 
cat model. The pharmaceutical composition can contain other 
pharmaceuticals, in conjunction with a vector according to 
the invention, when used to therapeutically treat AIDS. These 
other pharmaceuticals can be used in their traditional fashion 
(i.e., as antiviral agents to treat HIV infection). Examples of 
HIV agents include without limitation non-nucleoside 
reverse transcriptase inhibitors, protease inhibitors, entry or 
fusion inhibitors and integrase inhibitors 
0092. According to another embodiment, the present 
invention provides an antibody-based pharmaceutical com 
position comprising an effective amount of an isolated HIV 
antibody, or an affinity matured version, which provides a 
prophylactic or therapeutic treatment choice to reduce infec 
tion of the HIV virus. The antibody-based pharmaceutical 
composition of the present invention may be formulated by 
any number of strategies known in the art (e.g., see McGoff 
and Scher, 2000, Solution Formulation of Proteins/Peptides: 
In McNally, E.J., ed. Protein Formulation and Delivery. New 
York, N.Y.: Marcel Dekker; pp. 139-158: Akers and Defilip 
pis, 2000, Peptides and Proteins as Parenteral Solutions. In: 
Pharmaceutical Formulation Development of Peptides and 
Proteins. Philadelphia, Pa.; Talyor and Francis: pp. 145-177; 
Akers, et al., 2002, Pharm. Biotechnol. 14:47-127). A phar 
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maceutically acceptable composition Suitable for patient 
administration will contain an effective amount of the anti 
body in a formulation which both retains biological activity 
while also promoting maximal stability during storage within 
an acceptable temperature range. The pharmaceutical com 
positions can also include, depending on the formulation 
desired, pharmaceutically acceptable diluents, pharmaceuti 
cally acceptable carriers and/or pharmaceutically acceptable 
excipients, or any Such vehicle commonly used to formulate 
pharmaceutical compositions for animal or human adminis 
tration. The diluent is selected so as not to affect the biological 
activity of the combination. Examples of such diluents are 
distilled water, physiological phosphate-buffered saline, 
Ringer's Solutions, dextrose solution, and Hank's solution. 
The amount of an excipient that is useful in the pharmaceu 
tical composition or formulation of this invention is an 
amount that serves to uniformly distribute the antibody 
throughout the composition so that it can be uniformly dis 
persed when it is to be delivered to a subject in need thereof. 
It may serve to dilute the antibody to a concentration which 
provides the desired beneficial palliative or curative results 
while at the same time minimizing any adverse side effects 
that might occur from too high a concentration. It may also 
have a preservative effect. Thus, for the antibody having a 
high physiological activity, more of the excipient will be 
employed. On the other hand, for any active ingredient(s) that 
exhibit a lower physiological activity, a lesser quantity of the 
excipient will be employed. 
0093. The above described antibodies and antibody com 
positions or vaccine compositions, comprising at least one or 
a combination of the antibodies described herein, can be 
administered for the prophylactic and therapeutic treatment 
of HIV viral infection. 
0094. The present invention also relates to isolated 
polypeptides comprising the amino acid sequences of the 
light chains and heavy chains listed in Tables A.B and FIGS. 
10 A-C; the consensus sequences for the heavy and light 
chains of SEQID NOs: 1 and 2; and insertion sequences SEQ 
ID NOS:3 and 4. 
0095. In other related embodiments, the invention pro 
vides polypeptide variants that encode the amino acid 
sequences of the HIV antibodies listed in Tables A.B and FIG. 
10 A-C; the consensus sequences for the heavy and light 
chains of SEQID NOs: 1 and 2; and insertion sequences SEQ 
ID NOS:3 and 4. These polypeptide variants have at least 
70%, at least 75%, at least 80%, at least 85%, at least 90%, at 
least 95%, at least 96%, at least 97%, at least 98%, or at least 
99%, or greater, sequence identity compared to a polypeptide 
sequence of this invention, as determined using the methods 
described herein, (for example, BLAST analysis using stan 
dard parameters). One skilled in this art will recognize that 
these values can be appropriately adjusted to determine cor 
responding identity of proteins encoded by taking into amino 
acid similarity and the like. 
0096. The term “polypeptide' is used in its conventional 
meaning, i.e., as a sequence of amino acids. The polypeptides 
are not limited to a specific length of the product. Peptides, 
oligopeptides, and proteins are included within the definition 
of polypeptide, and Such terms can be used interchangeably 
herein unless specifically indicated otherwise. This term also 
includes post-expression modifications of the polypeptide, 
for example, glycosylations, acetylations, phosphorylations 
and the like, as well as other modifications known in the art, 
both naturally occurring and non-naturally occurring. A 
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polypeptide can be an entire protein, or a Subsequence 
thereof. Particular polypeptides of interest in the context of 
this invention are amino acid Subsequences comprising 
CDRs, VH and VL, being capable of binding an antigen or 
HIV-infected cell. 
0097. A polypeptide “variant, as the term is used herein, 
is a polypeptide that typically differs from a polypeptide 
specifically disclosed herein in one or more Substitutions, 
deletions, additions and/or insertions. Such variants can be 
naturally occurring or can be synthetically generated, for 
example, by modifying one or more of the above polypeptide 
sequences of the invention and evaluating one or more bio 
logical activities of the polypeptideas described herein and/or 
using any of a number of techniques well known in the art. 
0098. For example, certain amino acids can be substituted 
for other amino acids in a protein structure without appre 
ciable loss of its ability to bind other polypeptides (for 
example, antigens) or cells. Since it is the binding capacity 
and nature of a protein that defines that protein's biological 
functional activity, certain amino acid sequence Substitutions 
can be made in a protein sequence, and, accordingly, its 
underlying DNA coding sequence, whereby a protein with 
like properties is obtained. It is thus contemplated that various 
changes can be made in the peptide sequences of the disclosed 
compositions, or corresponding DNA sequences that encode 
said peptides without appreciable loss of their biological util 
ity or activity. 
0099. In many instances, a polypeptide variant will con 
tain one or more conservative substitutions. A "conservative 
substitution' is one in which an amino acid is substituted for 
another amino acid that has similar properties, such that one 
skilled in the art of peptide chemistry would expect the sec 
ondary structure and hydropathic nature of the polypeptide to 
be substantially unchanged. 
0100 Amino acid substitutions generally are based on the 
relative similarity of the amino acid side-chain Substituents, 
for example, their hydrophobicity, hydrophilicity, charge, 
size, and the like. Exemplary substitutions that take various of 
the foregoing characteristics into consideration are well 
known to those of skill in the art and include: arginine and 
lysine; glutamate and aspartate; serine and threonine; 
glutamine and asparagine; and valine, leucine and isoleucine. 
0101 “Homology' or “sequence identity” refers to the 
percentage of residues in the polynucleotide or polypeptide 
sequence variant that are identical to the non-variant 
sequence after aligning the sequences and introducing gaps, if 
necessary, to achieve the maximum percent homology. In 
particular embodiments, polynucleotide and polypeptide 
variants have at least about 70%, at least about 75%, at least 
about 80%, at least about 90%, at least about 95%, at least 
about 98%, or at least about 99% polynucleotide or polypep 
tide homology with a polynucleotide or polypeptide 
described herein. 
0102. Such variant polypeptide sequences will share 70% 
or more (i.e. 80%, 85%, 90%. 95%,97%.98%, 99% or more) 
sequence identity with the sequences recited in the applica 
tion. In additional embodiments, the described invention pro 
vides polypeptide fragments comprising various lengths of 
contiguous stretches of amino acid sequences disclosed 
herein. For example, peptide sequences are provided by this 
invention that comprise at least about 5, 10, 15, 20, 30, 40, 50. 
75, 100, 150, or more contiguous peptides of one or more of 
the sequences disclosed herein as well as all intermediate 
lengths there between. 
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0103) The invention also includes nucleic acid sequences 
encoding part or all of the light and heavy chains of the 
described inventive antibodies, and fragments thereof. Due to 
redundancy of the genetic code, variants of these sequences 
will exist that encode the same amino acid sequences. 
0104. The present invention also includes isolated nucleic 
acid sequences encoding the polypeptides for the heavy and 
light chains of the HIV antibodies listed in Tables A,B and 
FIG. 10 A-C; the consensus sequences for the heavy and light 
chains of SEQID NOs: 1 and 2; and insertion sequences SEQ 
ID NOS:3 and 4. 
0105. In other related embodiments, the described inven 
tion provides polynucleotide variants that encode the peptide 
sequences of the heavy and light chains of the HIV antibodies 
listed in Tables A,B and FIGS. 10 A-C; the consensus 
sequences for the heavy and light chains of SEQID NOs: 1 
and 2; and insertion sequences SEQID NOS:3 and 4. These 
polynucleotide variants have at least 70%, at least 75%, at 
least 80%, at least 85%, at least 90%, at least 95%, at least 
96%, at least 97%, at least 98%, or at least 99%, or greater, 
sequence identity compared to a polynucleotide sequence of 
this invention, as determined using the methods described 
herein, (for example, BLAST analysis using standard param 
eters). One skilled in this art will recognize that these values 
can be appropriately adjusted to determine corresponding 
identity of proteins encoded by two nucleotide sequences by 
taking into account codon degeneracy, amino acid similarity, 
reading frame positioning, and the like. 
0106 The terms “nucleic acid” and “polynucleotide" are 
used interchangeably herein to refer to single-stranded or 
double-stranded RNA, DNA, or mixed polymers. Polynucle 
otides can include genomic sequences, extra-genomic and 
plasmid sequences, and Smaller engineered gene segments 
that express, or can be adapted to express polypeptides. 
0107 An "isolated nucleic acid' is a nucleic acid that is 
Substantially separated from other genome DNA sequences 
as well as proteins or complexes such as ribosomes and poly 
merases, which naturally accompany a native sequence. The 
term encompasses a nucleic acid sequence that has been 
removed from its naturally occurring environment, and 
includes recombinant or cloned DNA isolates and chemically 
synthesized analogues or analogues biologically synthesized 
by heterologous systems. A substantially pure nucleic acid 
includes isolated forms of the nucleic acid. Accordingly, this 
refers to the nucleic acid as originally isolated and does not 
exclude genes or sequences later added to the isolated nucleic 
acid by the hand of man. 
0108. A polynucleotide “variant, as the term is used 
herein, is a polynucleotide that typically differs from a poly 
nucleotide specifically disclosed herein in one or more Sub 
stitutions, deletions, additions and/or insertions. Such vari 
ants can be naturally occurring or can be synthetically 
generated, for example, by modifying one or more of the 
polynucleotide sequences of the invention and evaluating one 
or more biological activities of the encoded polypeptide as 
described herein and/or using any of a number of techniques 
well known in the art. 
0109 Modifications can be made in the structure of the 
polynucleotides of the described invention and still obtain a 
functional molecule that encodes a variant or derivative 
polypeptide with desirable characteristics. When it is desired 
to alter the amino acid sequence of a polypeptide to create an 
equivalent, or even an improved, variant or portion of a 
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polypeptide of the invention, one skilled in the art typically 
will change one or more of the codons of the encoding DNA 
Sequence. 
0110 Typically, polynucleotide variants contain one or 
more Substitutions, additions, deletions and/or insertions, 
Such that the immunogenic binding properties of the polypep 
tide encoded by the variant polynucleotide is not substantially 
diminished relative to a polypeptide encoded by a polynucle 
otide sequence specifically set forth herein. 
0111. In additional embodiments, the described invention 
provides polynucleotide fragments comprising various 
lengths of contiguous stretches of sequence identical to or 
complementary to one or more of the sequences disclosed 
herein. For example, polynucleotides are provided by this 
invention that comprise at least about 10, 15, 20, 30, 40, 50. 
75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous 
nucleotides of one or more of the sequences disclosed herein 
as well as all intermediate lengths there between and encom 
pass any length between the quoted values, such as 16, 17, 18, 
19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 
100, 101, 102, 103, etc.; 150, 151,152, 153, etc.; and includ 
ing all integers through 200-500: 500-1,000. 
0112. In another embodiment of the invention, polynucle 
otide compositions are provided that are capable of hybridiz 
ing under moderate to high Stringency conditions to a poly 
nucleotide sequence provided herein, or a fragment thereof, 
or a complementary sequence thereof. Hybridization tech 
niques are well known in the art of molecular biology. For 
purposes of illustration, Suitable moderate stringent condi 
tions for testing the hybridization of a polynucleotide of this 
invention with other polynucleotides include prewashing in a 
solution of 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); 
hybridizing at 50-60° C., 5xSSC, overnight; followed by 
washing twice at 65° C. for 20 minutes with each of 2x, 0.5x, 
and 0.2xSSC containing 0.1% SDS. One skilled in the art will 
understand that the stringency of hybridization can be readily 
manipulated, such as by altering the salt content of the hybrid 
ization solution and/or the temperature at which the hybrid 
ization is performed. For example, in another embodiment, 
Suitable highly stringent hybridization conditions include 
those described above, with the exception that the tempera 
ture of hybridization is increased, for example, to 60-65°C. or 
65-70° C. 
0113. In some embodiments, the polypeptide encoded by 
the polynucleotide variant or fragment has the same binding 
specificity (i.e., specifically or preferentially binds to the 
same epitope or HIV strain) as the polypeptide encoded by the 
native polynucleotide. In some embodiments, the described 
polynucleotides, polynucleotide variants, fragments and 
hybridizing sequences, encode polypeptides that have a level 
of binding activity of at least about 50%, at least about 70%, 
and at least about 90% of that for a polypeptide sequence 
specifically set forth herein. 
0114. The polynucleotides of the described invention, or 
fragments thereof, regardless of the length of the coding 
sequence itself, can be combined with other DNA sequences, 
Such as promoters, polyadenylation signals, additional 
restriction enzyme sites, multiple cloning sites, other coding 
segments, and the like. Such that their overall length can vary 
considerably. A nucleic acid fragment of almost any length is 
employed. For example, illustrative polynucleotide segments 
with total lengths of about 10000, about 5000, about 3000, 
about 2000, about 1000, about 500, about 200, about 100, 
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about 50 base pairs in length, and the like, (including all 
intermediate lengths) are included in many implementations 
of this invention. 
0115. In some embodiments, the polynucleotide 
sequences provided herein are used as probes or primers for 
nucleic acid hybridization, for example, as PCR primers. The 
ability of such nucleic acid probes to specifically hybridize to 
a sequence of interest enables them to detect the presence of 
complementary sequences in a given sample. However, other 
uses also are encompassed by the described invention, Such as 
the use of the sequence information for the preparation of 
mutant species primers, or primers for use in preparing other 
genetic constructions. As such, nucleic acid segments of the 
described invention that include a sequence region of at least 
about a 15 nucleotide long contiguous sequence that has the 
same sequence as, or is complementary to, a 15 nucleotide 
long contiguous sequence disclosed herein is particularly 
useful. Longer contiguous identical or complementary 
sequences, for example, those of about 20, 30, 40, 50, 100, 
200, 500, 1000 (including all intermediate lengths) including 
full length sequences, and all lengths in between, also are 
used in some embodiments. 
0116 Polynucleotide molecules having sequence regions 
consisting of contiguous nucleotide stretches of 10-14, 15-20, 
30, 50, or even of 100-200 nucleotides or so (including inter 
mediate lengths as well), identical or complementary to a 
polynucleotide sequence disclosed herein, are particularly 
contemplated as hybridization probes for use in, for example, 
Southern and Northern blotting, and/or primers for use in, for 
example, PCR. The total size of fragment, as well as the size 
of the complementary stretch(es), ultimately depends on the 
intended use or application of the particular nucleic acid 
segment. Smaller fragments generally are used in hybridiza 
tion embodiments, wherein the length of the contiguous 
complementary region can be varied, such as between about 
15 and about 100 nucleotides, but larger contiguous comple 
mentarity stretches can be used, according to the length 
complementary sequences one wishes to detect. 
0117. The use of a hybridization probe of about 15-25 
nucleotides in length allows the formation of a duplex mol 
ecule that is both stable and selective. Molecules having 
contiguous complementary sequences over stretches greater 
than 12 bases in length can be utilized, though, in order to 
increase stability and selectivity of the hybrid, and thereby 
improve the quality and degree of specific hybrid molecules 
obtained. Nucleic acid molecules having gene-complemen 
tary stretches of 15 to 25 contiguous nucleotides, or even 
longer where desired, can be utilized. 
0118 Hybridization probes are selected from any portion 
of any of the sequences disclosed herein. All that is required 
is to review the sequences set forth herein, or to any continu 
ous portion of the sequences, from about 15-25 nucleotides in 
length up to and including the full length sequence, that one 
wishes to utilize as a probe or primer. The choice of probe and 
primer sequences is governed by various factors. For 
example, one may wish to employ primers from towards the 
termini of the total sequence. 
0119 Further included within the scope of the invention 
are vectors such as expression vectors, comprising a nucleic 
acid sequence according to the invention. Cells transformed 
with such vectors also are included within the scope of the 
invention. 
0120. The present invention also provides vectors and host 
cells comprising a nucleic acid of the invention, as well as 
Nov. 6, 2014 
recombinant techniques for the production of a polypeptide 
of the invention. Vectors of the invention include those 
capable of replication in any type of cell or organism, includ 
ing, for example, plasmids, phage, cosmids, and mini chro 
mosomes. In some embodiments, vectors comprising a poly 
nucleotide of the described invention are vectors suitable for 
propagation or replication of the polynucleotide, or vectors 
Suitable for expressing a polypeptide of the described inven 
tion. Such vectors are known in the art and commercially 
available. 
I0121 “Vector” includes shuttle and expression vectors. 
Typically, the plasmid construct also will include an origin of 
replication (for example, the ColE1 origin of replication) and 
a selectable marker (for example, amplicillin or tetracycline 
resistance), for replication and selection, respectively, of the 
plasmids in bacteria. An "expression vector” refers to a vector 
that contains the necessary control sequences or regulatory 
elements for expression of the antibodies including antibody 
fragment of the invention, in bacterial or eukaryotic cells. 
I0122. As used herein, the term "cell' can be any cell, 
including, but not limited to, that of a eukaryotic, multicellu 
lar species (for example, as opposed to a unicellular yeast 
cell). Such as, but not limited to, a mammaliancellor a human 
cell. A cell can be present as a single entity, or can be part of 
a larger collection of cells. Such a “larger collection of cells' 
can comprise, for example, a cell culture (either mixed or 
pure), a tissue (for example, endothelial, epithelial, mucosa or 
other tissue), an organ (for example, lung, liver, muscle and 
other organs), an organ system (for example, circulatory sys 
tem, respiratory system, gastrointestinal system, urinary sys 
tem, nervous system, integumentary system or other organ 
system), or an organism (e.g., a bird, mammal, or the like). 
I0123 Polynucleotides of the invention may synthesized, 
whole or in parts that then are combined, and inserted into a 
vector using routine molecular and cell biology techniques, 
including, for example, Subcloning the polynucleotide into a 
linearized vector using appropriate restriction sites and 
restriction enzymes. Polynucleotides of the described inven 
tion are amplified by polymerase chain reaction using oligo 
nucleotide primers complementary to each strand of the poly 
nucleotide. These primers also include restriction enzyme 
cleavage sites to facilitate Subcloning into a vector. The rep 
licable vector components generally include, but are not lim 
ited to, one or more of the following: a signal sequence, an 
origin of replication, and one or more marker or selectable 
genes. 
0.124. In order to express a polypeptide of the invention, 
the nucleotide sequences encoding the polypeptide, or func 
tional equivalents, may be inserted into an appropriate 
expression vector, i.e., a vector that contains the necessary 
elements for the transcription and translation of the inserted 
coding sequence. Methods well known to those skilled in the 
art may be used to construct expression vectors containing 
sequences encoding a polypeptide of interest and appropriate 
transcriptional and translational control elements. These 
methods include in vitro recombinant DNA techniques, syn 
thetic techniques, and in vivo genetic recombination. Such 
techniques are described, for example, in Sambrook, J., et al. 
(1989) Molecular Cloning, A Laboratory Manual, Cold 
Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et 
al. (1989) Current Protocols in Molecular Biology, John 
Wiley & Sons, New York. N.Y. 
0.125. The present invention also provides kits useful in 
performing diagnostic and prognostic assays using the anti 
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bodies, polypeptides and nucleic acids of the present inven 
tion. Kits of the present invention include a suitable container 
comprising an HIV antibody, a polypeptide or a nucleic acid 
of the invention in either labeled or unlabeled form. In addi 
tion, when the antibody, polypeptide or nucleic acid is Sup 
plied in a labeled form suitable for an indirect binding assay, 
the kit further includes reagents for performing the appropri 
ate indirect assay. For example, the kit may include one or 
more Suitable containers including enzyme substrates or 
derivatizing agents, depending on the nature of the label. 
Control samples and/or instructions may also be included. 
The present invention also provide kits for detecting the pres 
ence of the HIV antibodies or the nucleotide sequence of the 
HIV antibody of the present invention in a biological sample 
by PCR or mass spectrometry. 
0126 “Label as used herein refers to a detectable com 
pound or composition that is conjugated directly or indirectly 
to the antibody so as to generate a “labeled' antibody. A label 
can also be conjugated to a polypeptide and/or a nucleic acid 
sequence disclosed herein. The label can be detectable by 
itself (for example, radioisotope labels or fluorescent labels) 
or, in the case of an enzymatic label, can catalyze chemical 
alteration of a Substrate compound or composition that is 
detectable. Antibodies and polypeptides of the described 
invention also can be modified to include an epitope tag or 
label, for example, for use in purification or diagnostic appli 
cations. Suitable detection means include the use of labels 
Such as, but not limited to, radionucleotides, enzymes, coen 
Zymes, fluorescers, chemiluminescers, chromogens, enzyme 
Substrates or co-factors, enzyme inhibitors, prosthetic group 
complexes, free radicals, particles, dyes, and the like. 
0127. According to another embodiment, the present 
invention provides diagnostic methods. Diagnostic methods 
generally involve contacting a biological sample obtained 
from a patient, such as, for example, blood, serum, Saliva, 
urine, sputum, a cell Swab sample, or a tissue biopsy, with an 
HIV antibody and determining whether the antibody prefer 
entially binds to the sample as compared to a control sample 
or predetermined cut-off value, thereby indicating the pres 
ence of the HIV virus. 
0128. According to another embodiment, the present 
invention provides methods to detect the presence of the HIV 
antibodies of the present invention in a biological sample 
from a patient. Detection methods generally involve obtain 
ing a biological sample from a patient, such as, for example, 
blood, serum, saliva, urine, sputum, a cell Swab Sample, or a 
tissue biopsy and isolating HIV antibodies or fragments 
thereof, or the nucleic acids that encode an HIV antibody, and 
assaying for the presence of an HIV antibody in the biological 
sample. Also, the present invention provides methods to 
detect the nucleotide sequence of an HIV antibody in a cell. 
The nucleotide sequence of an HIV antibody may also be 
detected using the primers disclosed herein. The presence of 
the HIV antibody in a biological sample from a patient may be 
determined utilizing known recombinant techniques and/or 
the use of a mass spectrometer. 
0129. In another embodiment, the present invention pro 
vides a method for detecting an HIV antibody comprising a 
heavy chain comprising a highly conserved consensus 
sequence and a light chain comprising a highly conserved 
consensus sequence in a biological sample, comprising 
obtaining an immunoglobulin-containing biological sample 
from a mammalian Subject, isolating an HIV antibody from 
said sample, and identifying the highly conserved consensus 
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sequences of the heavy chain and the light chain. The biologi 
cal sample may be blood, serum, saliva, urine, sputum, a cell 
Swab Sample, or a tissue biopsy. The amino acid sequences 
may be determined by methods known in the art including, for 
example, PCR and mass spectrometry. 
0.130. The term “assessing includes any form of measure 
ment, and includes determining if an element is present or not. 
The terms “determining”, “measuring”, “evaluating, 
'assessing and “assaying are used interchangeably and 
include quantitative and qualitative determinations. Assess 
ing may be relative or absolute. "Assessing the presence of 
includes determining the amount of Something present, and/ 
or determining whether it is present or absent. As used herein, 
the terms “determining.” “measuring.” and “assessing.” and 
'assaying are used interchangeably and include both quan 
titative and qualitative determinations. 
II. Method of Reducing Viral Replication 
I0131 Methods for reducing an increase in HIV virus titer, 
virus replication, virus proliferation or an amount of an HIV 
viral protein in a Subject are further provided. According to 
another aspect, a method includes administering to the Sub 
ject an amount of an HIV antibody effective to reduce an 
increase in HIV titer, virus replication oran amount of an HIV 
protein of one or more HIV strains or isolates in the subject. 
0.132. According to another embodiment, the present 
invention provides a method of reducing viral replication or 
spread of HIV infection to additional host cells or tissues 
comprising contacting a mammaliancell with the antibody, or 
a portion thereof, which binds to an antigenic epitope on 
gp120. 
III. Method of Treatment 
0.133 According to another embodiment, the present 
invention provides a method for treating a mammal infected 
with a virus infection, such as, for example, HIV, comprising 
administering to said mammala pharmaceutical composition 
comprising the HIV antibodies disclosed herein. According 
to one embodiment, the method for treating a mammal 
infected with HIV comprises administering to said mammala 
pharmaceutical composition that comprises an antibody of 
the present invention, or a fragment thereof. The composi 
tions of the invention can include more than one antibody 
having the characteristics disclosed (for example, a plurality 
or pool of antibodies). It also can include other HIV neutral 
izing antibodies as are known in the art, for example, but not 
limited to, VRCO1, PG9 and b12. 
I0134) Passive immunization has proven to be an effective 
and safe strategy for the prevention and treatment of viral 
diseases. (See, for example, Keller et al., Clin. Microbiol. 
Rev. 13:602-14 (2000); Casadevall, Nat. Biotechnol. 20:114 
(2002); Shibata et al., Nat. Med. 5:204-10 (1999); and Iga 
rashi et al., Nat. Med. 5:211-16 (1999), each of which are 
incorporated herein by reference). Passive immunization 
using human monoclonal antibodies provides an immediate 
treatment strategy for emergency prophylaxis and treatment 
of HIV. 
0.135 Subjects at risk for HIV-related diseases or disorders 
include patients who have come into contact with an infected 
person or who have been exposed to HIV in some other way. 
Administration of a prophylactic agent can occur prior to the 
manifestation of symptoms characteristic of HIV-related dis 
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ease or disorder, Such that a disease or disorder is prevented 
or, alternatively, delayed in its progression. 
0136. For in vivo treatment of human and non-human 
patients, the patient is administered or provided a pharmaceu 
tical formulation including an HIV antibody of the invention. 
When used for in vivo therapy, the antibodies of the invention 
are administered to the patient in therapeutically effective 
amounts (i.e., amounts that eliminate or reduce the patients 
viral burden). The antibodies are administered to a human 
patient, in accord with known methods, such as intravenous 
administration, for example, as a bolus or by continuous 
infusion over a period of time, by intramuscular, intraperito 
neal, intracerobrospinal, Subcutaneous, intra-articular, intra 
synovial, intrathecal, oral, topical, or inhalation routes. The 
antibodies can be administered parenterally, when possible, 
at the target cell site, or intravenously. In some embodiments, 
antibody is administered by intravenous or Subcutaneous 
administration. Therapeutic compositions of the invention 
may be administered to a patient or Subject systemically, 
parenterally, or locally. The above parameters for assessing 
Successful treatment and improvement in the disease are 
readily measurable by routine procedures familiar to a phy 
S1C1a. 
0.137 For parenteral administration, the antibodies may 
formulated in a unit dosage injectable form (solution, Suspen 
Sion, emulsion) in association with a pharmaceutically 
acceptable, parenteral vehicle. Examples of such vehicles 
include, but are not limited, water, Saline, Ringer's solution, 
dextrose solution, and 5% human serum albumin. Nonacque 
ous vehicles include, but are not limited to, fixed oils and ethyl 
oleate. Liposomes can be used as carriers. The vehicle may 
contain minor amounts of additives such as Substances that 
enhance isotonicity and chemical stability, such as, for 
example, buffers and preservatives. The antibodies can be 
formulated in such vehicles at concentrations of about 1 
mg/ml to 10 mg/ml. 
0.138. The dose and dosage regimen depends upon a vari 
ety of factors readily determined by a physician, Such as the 
nature of the infection, for example, its therapeutic index, the 
patient, and the patient's history. Generally, a therapeutically 
effective amount of an antibody is administered to a patient. 
In some embodiments, the amount of antibody administered 
is in the range of about 0.1 mg/kg to about 50 mg/kg of patient 
body weight. Depending on the type and severity of the infec 
tion, about 0.1 mg/kg to about 50 mg/kg body weight (for 
example, about 0.1-15 mg/kg/dose) of antibody is an initial 
candidate dosage for administration to the patient, whether, 
for example, by one or more separate administrations, or by 
continuous infusion. The progress of this therapy is readily 
monitored by conventional methods and assays and based on 
criteria known to the physician or other persons of skill in the 
art. The above parameters for assessing Successful treatment 
and improvement in the disease are readily measurable by 
routine procedures familiar to a physician. 
0.139. Other therapeutic regimens may be combined with 
the administration of the HIV antibody of the present inven 
tion. The combined administration includes co-administra 
tion, using separate formulations or a single pharmaceutical 
formulation, and consecutive administration in either order, 
wherein preferably there is a time period while both (or all) 
active agents simultaneously exert their biological activities. 
Such combined therapy can result in a synergistic therapeutic 
effect. The above parameters for assessing Successful treat 
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ment and improvement in the disease are readily measurable 
by routine procedures familiar to a physician. 
0140. The terms “treating or “treatment” or “alleviation” 
are used interchangeably and refer to both therapeutic treat 
ment and prophylactic or preventative measures; wherein the 
object is to prevent or slow down (lessen) the targeted patho 
logic condition or disorder. Those in need of treatment 
include those already with the disorder as well as those prone 
to have the disorder or those in whom the disorder is to be 
prevented. A subject or mammal is successfully “treated for 
an infection if, after receiving a therapeutic amount of an 
antibody according to the methods of the present invention, 
the patient shows observable and/or measurable reduction in 
or absence of one or more of the following: reduction in the 
number of infected cells or absence of the infected cells; 
reduction in the percent of total cells that are infected; and/or 
relief to Some extent, one or more of the symptoms associated 
with the specific infection; reduced morbidity and mortality, 
and improvement in quality of life issues. The above param 
eters for assessing Successful treatment and improvement in 
the disease are readily measurable by routine procedures 
familiar to a physician. 
0.141. The term “therapeutically effective amount” refers 
to an amount of an antibody or a drug effective to treat a 
disease or disorder in a Subject or mammal. 
0.142 Administration “in combination with one or more 
further therapeutic agents includes simultaneous (concur 
rent) and consecutive administration in any order. 
0.143 “Carriers' as used herein include pharmaceutically 
acceptable carriers, excipients, or stabilizers that are nontoxic 
to the cell or mammal being exposed thereto at the dosages 
and concentrations employed. Often the physiologically 
acceptable carrier is an aqueous pH buffered solution. 
Examples of physiologically acceptable carriers include, but 
not limited to, buffers such as phosphate, citrate, and other 
organic acids; antioxidants including, but not limited to, 
ascorbic acid; low molecular weight (less than about 10 resi 
dues) polypeptide; proteins, such as, but not limited to, serum 
albumin, gelatin, or immunoglobulins; hydrophilic polymers 
Such as, but not limited to, polyvinylpyrrolidone; amino acids 
Such as, but not limited to, glycine, glutamine, asparagine, 
arginine or lysine; monosaccharides, disaccharides, and other 
carbohydrates including, but not limited to, glucose, man 
nose, or dextrins; chelating agents such as, but not limited to, 
EDTA; Sugar alcohols such as, but not limited to, mannitol or 
Sorbitol; salt-forming counterions such as, but not limited to, 
Sodium; and/or nonionic Surfactants such as, but not limited 
to, TWEEN. polyethylene glycol (PEG), and PLURONICS. 
0144. Where a value of ranges is provided, it is understood 
that each intervening value, to the tenth of the unit of the lower 
limit unless the context clearly dictates otherwise, between 
the upper and lower limit of that range and any other stated or 
intervening value in that stated range is encompassed within 
the invention. The upper and lower limits of these smaller 
ranges which may independently be included in the Smaller 
ranges is also encompassed within the invention, Subject to 
any specifically excluded limit in the stated range. Where the 
stated range includes one or both of the limits, ranges exclud 
ing either both of those included limits are also included in the 
invention. 
(0145 Unless defined otherwise, all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
invention belongs. Although any methods and materials simi 
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lar or equivalent to those described herein can also be used in 
the practice or testing of the present invention, the preferred 
methods and materials are now described. All publications 
mentioned herein are incorporated herein by reference in 
their entireties. 
0146. As used herein and in the appended claims, the 
singular forms “a”, “and” and “the include plural references 
unless the context clearly dictates otherwise 
0147 Publications disclosed herein are provided solely 
for their disclosure prior to the filing date of the present 
invention. Nothing herein is to be construed as an admission 
that the present invention is not entitled to antedate such 
publication by virtue of prior invention. Further, the dates of 
publication provided may be different from the actual publi 
cation dates which may need to be independently confirmed. 
0148. Each of the applications and patents cited in this 
text, as well as each document or reference, patient or non 
patient literature, cited in each of the applications and patents 
(including during the prosecution of each issued patent; 
“application cited documents'), and each of the PCT and 
foreign applications or patents corresponding to and/or 
claiming priority from any of these applications and patents, 
and each of the documents cited or referenced in each of the 
application cited documents, are hereby expressly incorpo 
rated herein by reference in their entirety. More generally, 
documents or references are cited in this text, either in a 
Reference List before the claims; or in the text itself, and, 
each of these documents or references (“herein-cited refer 
ences”), as well as each document or reference cited in each 
of the herein-cited references (including any manufacturers 
specifications, instructions, etc.), is hereby expressly incor 
porated herein by reference. 
014.9 The following non-limiting examples serve to fur 
ther illustrate the present invention. 
Example 1 
Materials, Methods and Instrumentation 
0150. Samples. 
0151 Human samples were collected after signed 
informed consent in accordance with Institutional Review 
Board (IRB)-reviewed protocols by all participating institu 
tions. Patient 1 was selected from a cohort of long-term non 
progressors followed at the Aaron Diamond Aids Research 
Center, NewYork. Patients 3 and 8 were selected from a group 
ofelite controllers that were followed at the Ragon Institute in 
Boston. Patients 1,3 and 8 were selected based on their broad 
neutralizing serum activity against a standard panel of HIV 
isolates. Patient 12 was selected from the Protocol G Cohort 
of the “International Aids Vaccine Initiative' based on broad 
serum neutralizing activity. 
0152 Staining, Single-Cell Sorting and Antibody Clon 
ing. 
0153 Staining and single cell sorting of 2CC-Core and 
gp140 specific Ig+ memory B cells was performed (J. F. 
Scheid et al., Nature 458, 636 (Apr. 2, 2009)). Briefly, 
CD19+B cells were enriched from peripheral blood mono 
nuclear cells using antihuman CD19 magnetic MACS beads 
(Miltenyi Biotec) and subsequently stained with anti human 
CD20 and antihuman IgG antibodies (Becton Dickinson) as 
well as biotinylated 2CC-Core (B. Dey et al., PLoS Pathog5, 
e1000445 (May, 2009)) or YU2-gp140 trimer (R. Diskin, P. 
M. Marcovecchio, P. J. Bjorkman, Nat Struct Mol Biol 17, 
608 (May, 2010)) followed by detection with streptavidin 
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coupled phycoerythrin (PE, Beckton Dickinson). Single cells 
were sorted on a FACSAria III cell sorter (Becton Dickinson), 
excluding cell doublets, into 96-well PCR plates (Denville) 
containing 4 ul/well of ice-cold 0.5x phosphate-buffered 
saline (PBS) containing 10 mM DTT, 8 U RNAsin(R) 
(Promega), 0.4 U 5'-3' Prime RNAse InhibitorTM (Eppen 
dorf). Plates were sealed with Microseal R. F. Film (BioRad), 
immediately frozen on dry ice before storage at -80° C. 
0154 cDNA synthesis and Ig amplification were per 
formed (H. Wardemann et al., Science 301, 1374 (Sep. 5, 
2003)) with following modifications: 
0155 Instead of using the original primer sets, first and 
second immunoglobulin specific PCRs were carried out using 
the primers described in Table 1 in a semi-nested approach. 
Cloning of heavy and light chain PCR products into their 
respective expression vectors was performed and 100% iden 
tity of cloned expression plasmids with the original PCR 
product confirmed by sequencing before expression of the 
antibodies in HEK 293 cells. 
0156 ELISAs. 
(O157 High-binding 96-well ELISA plates (Costar) were 
coated overnight with 100 ng/well of purified antigens 
(gp140, gp120, gp41, gp120' and 2CC-core) (B. Dey et al., 
PLoS Pathog5, e1000445 (May, 2009)) and mutant proteins 
(gp120 D368R, gp120 I420R) in PBS. After washing, plates 
were blocked 2 h with 2% BSA, 1 uM EDTA, 0.05% Tween 
PBS (Blocking buffer) and then, incubated 2h with IgG anti 
bodies diluted at 4 ug/ml and several consecutive 1:4 dilutions 
in PBS. After washing, the plates were developed by incuba 
tion for 1 h with goat HRP-conjugated anti-mouse IgG (Jack 
son ImmunoReseach) (at 0.8 ug/ml in blocking buffer) and by 
adding 100 ul of HRP chromogenic substrate (ABTS solu 
tion, Invitrogen). Optical densities were measured at 405 nm. 
(ODaos ) using an ELISA microplate reader (Molecular 
Devices). Background values given by incubation of PBS 
alone in coated wells were subtracted. IgG Antibodies were 
tested for polyreactivity (H. Mouquet et al., Nature 467,591 
(Sep. 30, 2010)) and considered polyreactive when they rec 
ognized at least two structurally different antigens out of the 
four tested: ssDNA, dsDNA, insulin, and LPS. Threshold 
values for reactivity were determined by using control anti 
bodies mGO53 (negative), eiJB40 (low positive), and ED38 (high positive). 
0158 Neutralization Assays: 
0159 Neutralization screens were performed (D.C. Mon 
tefiori, Curr Protoc Immunol Chapter 12, Unit 1211 (Janu 
ary, 2005)). In brief, neutralization was detected as reduction 
in luciferase reporter gene expression after single round 
infection in Tzm-b1 cells. In order to rule out unspecific 
antiviral activity in antibody samples Mul V (murine leuke 
mia virus) was used as a negative control. 
(0160 Clone Specific Identification of Bone Marrow 
Plasma Cells. 
0.161 Bone marrow plasma cells were stained with anti 
human CD138 and anti CD19 antibodies (Becton Dickinson) 
after Ficoll purification of mononuclear cells from bone mar 
row aspirates using Ficoll-Paque (GE Healthcare). CD138+ 
CD19+ human plasma cells were bulk sorted on a FACSAri 
aIII cell sorter (Becton Dickinson) and RNA isolation per 
formed on 100.000 cells using Trizol LS reagent (Invitrogen) 
according to the manufacturers instructions. RNA was 
reverse transcribed using SuperScript III reverse transcriptase 
(Invitrogen) according to manufacturers instructions. cDNA 
was then subjected to Immunoglobulin specific PCR with 
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following modifications: 1 ul of cDNA was amplified in 2 
rounds of nested immunoglobulin heavy chain clone specific 
PCR using first round forward leader and constant region 
reverse primers shown in Table 1 followed by clone specific 
forward and reverse primers designed based on sequencing 
results from single cell analysis. PCR products were gel puri 
fied and cloned into TOPOTA vectors (Invitrogen) according 
to the manufacturers instructions. Colonies were screened by 
PCR with clone specific primers and sequenced. 
0162 Surface Plasmon Resonance. 
0163 All experiments were performed with a Biacore 
T100 (Biacore, Inc) in HBS-EP+ running buffer (Biacore, 
Inc) at 25°C. as described previously (Mouquet 2010).YU-2 
gp140 and 2CC-core proteins at 12.5 Lig/mL were immobi 
lized on CM5 chips (Biacore, Inc.) by amine coupling at pH 
4.5 resulting in an immobilization level of 100 RUs. For 
kinetic measurements on the gp140- and 2CC-core-deriva 
tized chips, IgGs were injected through flow cells at 700 nM 
and 4 successive 1:2-dilutions in HBS-EP+ running buffer 
(Biacore, Inc.) at flow rates of 40 uL/min with 3 min associa 
tion and 5 min dissociation. The sensor Surface was regener 
ated between each experiment with a 30 second injection of 
10 mM glycine-HCl pH 2.5 at a flow rate of 50 uL/min. Off 
rate (k(s)), on rate (k, (M's') and binding constants (K, 
(M) or K. (M) were calculated after subtraction of back 
grounds (binding to control flow cells and signal of the HBS 
EP+ running buffer) using Biacore T100 Evaluation software 
using the kinetic analysis and the 1:1 binding model. The 
sensorgrams showed in FIG.2 and FIG. 8 are derived from the 
Biacore data processing using Scrubber 2 software (Center for 
Biomolecular Interaction Analysis, University of Utah). 
(0164. CD4i Site Induction. 
(0165 293T cells were transfected with gp160'Ac or 
gp160'Ac in a pMX-IRES-GFP construct (Pietzsch et al. 
2010) using FugeneTM6 (Roche) at a 1:2 plasmid:Fugene 
ratio. After 48 hours 293T cells were washed with PBS and 
detached with Trypsin-free cell dissociation buffer (Gibco) 
and resuspended at a concentration of 107 cells/ml in FACS 
buffer (1xPBS, 2% FBS, 2 mM EDTA). SCD4 (Progenics 
Pharmaceuticals, Inc.) and mAbs were added to gp160-ex 
pressing 293T cells in a 1:4 dilution series starting with a final 
concentration of 40 ug/ml. mGO is a negative control anti 
body that does not bind to gp160Ac (H. Mouquet et al., Nature 
467, 591 (Sep. 30, 2010)). After incubation for 15 min on ice 
cells were split and stained for 25 min on ice with an 
Alexa647-labeled CD4-induced site mab (3-67: (J. F. Scheid 
et al., Nature 458,636 (Apr. 2, 2009)) or an Alexa647-labeled 
control mAb (i.e. PG16: L. M. Walkeret al., Science 326, 285 (Oct. 9, 2009)) or 2G12 for gp160' and 2G12 for 
gp160'’). Antibody labeling was performed by using 
Alexa Fluor R 647 Microscale Protein Labeling Kit (Invitro 
gen). Cells were analyzed on an LSRFortessa cell analyzer 
(BD Bioscience). 
0166 Crystallization. 
(0167. The 3BNC60 IgG was expressed by transient 
expression in HEK293-6E cells and prepared the Fab frag 
ment was prepared by papain cleavage (R. Diskin, P. M. 
Marcovecchio, P. J. Bjorkman, Nat Struct Mol Biol 17, 608 
(May, 2010). Crystallization screens were conducted at 20° 
C. by vapor diffusion in nL sitting drops using a Mosquito TM 
(TTP LabTech) crystallization robot on MRC crystallization 
plates (Jena Bioscience). We combined 3BNC60 Fab at a 
concentration of 9.5 mg/ml with reservoir solution in a 1:1 
ratio to create 400 mL drops. Initial crystallization hits were 
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obtained using the PEGRX HTTM (Hampton Research) crys 
tallization screen and further optimized manually. Crystals 
suitable for data collection grew after several weeks in 11.7% 
polyethylene glycol 20,000, 0.1 M sodium acetate pH 5.0, 
100 mM potassium/sodium tartrate, 20 mM lithium sulfate, 
10 mMN-Cyclohexyl-2-aminoethanesulfonic acid (CHES) 
pH 9.5 in the monoclinic space group P2 with two Fabs in the 
asymmetric unit. Crystals were soaked in reservoir Solution 
supplemented with 15% glycerol for 2 hours before immers 
ing in reservoir solution supplemented with 30% glyceroland 
flash cooling in liquid nitrogen. Diffraction data were col 
lected at the Stanford Synchrotron Radiation Lightsource 
(SSRL) beam-line 12-2 at 100 K using a Pilatus 6M detector. 
Data were indexed, integrated, and scaled using XDS W. 
Kabsch, Acta Crystallogr D Biol Crystallogr 66, 125 (Feb 
ruary, 2010) (Table 8). Molecular replacement was conducted 
using Phaser with the V and C1 domains from the anti 
tumor antibody CTM01 (PDB code 1AD9) and with the V, 
and C, domains of the anti-gp120 b13 antibody (PDB code 
3IDX) as search models. Model building and refinement to 
2.65 A resolution was done iteratively using Phenix P. Ems 
ley, B. Lohkamp, W. G. Scott, K. Cowtan, Acta CrystallogrD 
Biol Crystallogr66,486 (April, 2010) and Coot (P. Emsley, B. 
Lohkamp, W. G. Scott, K. Cowtan, Acta Crystallogr D Biol 
Crystallogr 66,486 (April, 2010)). The structure was refined 
using a maximum-likelihood target function and non-crystal 
lographic symmetry restraints. The final model (R, 20. 
7%; R =25.7%) includes 6478 protein atoms, 146 water 
molecules and 28 sugar atoms (Table 8). 91.9%, 7.6% and 
0.5% of the residues were in the favored, allowed, and disal 
lowed regions, respectively, of the Ramachandran plot. Struc 
tural analyses and visualization were done using PyMol (The 
PyMOL Molecular Graphics System, Version 1.3, Schrod 
inger, LLC). The 3BNC60 structure consists of residues 
3-205 for the light chain (including the first N-acetylglu 
cosamine within an N-linked carbohydrate attached to 
Asn72) and 2-217 for the heavy-chain. Residues at the ter 
mini residues and residues 133-140 within the C1 domain 
are disordered. 
(0168 
0169. IgG was purified from serum using ProteinG 
Sepharose (GE Healthcare) according to the manufacturers 
instructions. IgGs were then digested with immobilized 
papain (Pierce) and digested Fab-Fc fragment mixes incu 
bated with saturating quantities of biotinylated 2CC-Core 
protein. Streptavidin coupled Dynabeads (Invitrogen) were 
added after incubation for 15 minutes at room temperature 
and subjected to 10 rounds of washing with Phosphate Buff 
ered Saline (Gibco). Bound Fab fragments were eluted with 
lithium dodecyl sulfate buffer (Invitrogen) at 95 Cand sample 
purity confirmed with SDS-polyacrylamide gel electrophore 
sis followed by silver stain or coomassie staining before 
analysis by mass spectrometry. 
0170 Isolated Fab fragments were reduced with dithio 
threitol, alkylated using iodoacetamide, resolved by 1D gel 
electrophoresis on a 4-12% NuPAGE Novex Bis-Tris gel 
(Invitrogen), and stained with Coomassie Blue (Thermo 
Fisher). The Fab fragments were excised from the gel, and 
digested using 200 ng of trypsin (Promega). The resulting 
peptides were isolated using reverse phase resin (PORS 20 
R2, Applied Biosystem) and eluted using an aliquot of 40% 
acetonitrile in 0.5% acetic acid and a second aliquot of 80% 
acetonitrile in 0.5% acetic acid. Acetonitrile was removed 
using a speedvac (Thermo Fisher Scientific) and aliquots of 
Mass Spectrometry. 
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the remaining Solution pressure loaded onto self-packed 
Pico Frit(R) column (New Objective, Woburn, Mass.) with 
integrated emitter tip (360 um O.D., 50 um I.D., 10 um tip), 
packed with 6 cm of reverse-phase C18 material (ReproSil 
Pur C18-AQ, 3 um beads from Dr. Maisch GmbH) and inter 
faced to a Agilent 1200 series HPLC system (Agilent) with 
either a LTQ OrbitrapTM XL mass spectrometer or a LTQ 
Orbitrap VelosTM mass spectrometer (Thermo Fisher Scien 
tific) using a home-built micro electrospray source. The pep 
tides were eluted into the mass spectrometer with the follow 
ing gradient: 0 to 5% B in 5 min, 40% B in 125 min, 60% B 
in 150 min, 100% B in 165 min(A=0.1 Macetic acid, B=70% 
acetonitrile in 0.1 M acetic acid, flow rate 90 mL/min). Both 
instruments were operated in the data dependent mode and 
for both mass spectrometers the target value was set to 5e5 
ions and a resolution of 60,000 (at 400 m/z). For analysis on 
the LTQ OrbitrapTMXL a full scan was followed by 8 MS/MS 
scans on the 8 most abundant ions from that full scan. The 
peptides (only charge states-1) were isolated with a 2 Da 
window, target window of 1e4 ions, dissociated via CAD 
(normalized collision energy–35, activation Q=0.25, activa 
tion time 30 msec) and mass analyzed in the LTQ. For analy 
sis on the LTQ OrbitrapTMVelos a full scan was followed by 
10 MS/MS scans at 7,500 resolution on the 10 most abundant 
ions from the immediate preceding full scan. The peptides 
(only charge state-2) were isolated with a 3 Da window, 
target window of 2e5 ions, dissociated via HCD (normalized 
collision energy-40, activation time 0.100 msec) and mass 
analyzed in the Orbitrap. For either instrument the ions 
selected for MS/MS were set on an exclusion list for 30 
seconds. The resulting MS/MS spectra were searched against 
the Human IPI and in-house patient specific IgG database 
using Xtandem, peptides were automatically compared to 
tryptic peptides in the human IPI and our in-house patient 
specific database. Peptide hits corresponding to patient spe 
cific IgG were manually confirmed. 
0171 
0172 All multiple sequence alignments were conducted 
using CLUSTALW2 with default parameters (weight matrix: 
GONNET for proteins and UIB for DNA, gap open=10, gap 
extension 0.1). Alignments shading were generated using 
TeXshade package. 
0173 
0174 The consensus sequences for multiple alignments 
were generated based on identity and similarity between resi 
dues (>=70%). The amino acids were grouping due similarity 
as: FYW, ILVM, RK, DE, GA, ST and NQ. 
0175 
0176 The relationship between sequences was generated 
using the Neighbor-Joining method. The bootstrap consensus 
tree inferred from 1000 replicates was taken to represent the 
relationship. Branches corresponding to partitions repro 
duced in less than 50% bootstrap replicates are collapsed. The 
percentage of replicate trees in which the associated sequence 
clustered together in the bootstrap test (1000 replicates) are 
shown next to the branches. The tree is drawn to scale, with 
branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. The evolution 
ary distances were computed using the number of differences 
method and are in the units of the number of amino acid 
differences per sequence. All ambiguous positions were 
removed for each sequence pair. Evolutionary analyses were 
conducted in MEGAS. 
Multiple Sequence Alignments. 
Alignment Consensus. 
Phylogenetic Germline Trees. 
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0177 R/S Ratio Calculation. 
0.178 DNA sequences were superposed over the proteins 
alignments to replacement/substitution calculation. All gaps 
positions were removed from the analysis. The R/S ratio 
analysis was conducted using Perl Scripts. 
Example 2 
Isolating HIV Antibodies 
0179 To determine whether HIV antibody cloning is lim 
ited because of somatic mutation, a new series of primers was 
designed to avert this potential problem (Table 1). The new 
primer set was tested by sorting B cells that bind to an HIV 
gp120 core protein lacking the V1-3 loops and containing a 
pair of stabilizing disulfide bonds (2CC-core). In contrast to 
the re-surfaced bait used to clone VRCO1, the 2CC-core bait 
also allows capture of antibodies to the CD4-induced co 
receptor binding site (CD4i). 
0180. In side-by-side comparisons, the new primer set 
increased recovery of IgEI chains when compared to the initial 
primer set (FIG. 4(a)). The antibodies obtained with the new 
primer set were more mutated (average 35.6 vs. 19.8 p=<0. 
0001 and maximum 85 vs. 50 for IgEI) and included clones 
that were not found with the original primer set (FIG. 4(a)). 
To determine whether the new primers rescue VRC01-like 
antibodies from cells that had been sorted with YU2 gp140, 
frozen cINA samples from that individual which had already 
been examined exhaustively with the original primerset with 
out producing any VRCO1 related clones were examined. In 
80 wells, 3 antibodies corresponding to VRC01 variants as 
determined by the IgEI and Ig|L sequences were found (FIGS. 
5A and B). It was concluded that VRC01-like antibodies were 
captured by the gp140 trimer, and that primers that were 
specifically designed to clone highly mutated antibodies cap 
tured a larger fraction of anti-HIV antibodies from the 
memory B cells of patients with high titers of broadly neu 
tralizing antibodies. 
0181 Four unrelated HIV infected individuals, including 
2 Caucasians, 1 Hispanic and 1 African donor, showing high 
titers of broadly neutralizing antibodies were examined using 
the 2CC-core bait, including 2 individuals whose previously 
cloned antibodies could not account for their serologic activ 
ity (Table 2 and FIGS. 6A and B). 576 antibodies representing 
201 different unique and diversified clones were obtained 
from a starting population of 1.5x10 IgG" memory B cells 
(Table 3). 
Example 3 
Binding Specificity of HIV Antibodies 
0182. The size of the antibody clones captured by 2CC 
core bait differed widely ranging from 2-76 diversified mem 
bers (Table 3). To determine whether the antibodies captured 
by the 2CC-core bind to the HIV spike, ELISAs were per 
formed usingYU2 gp120 on representative members of each 
expanded clone. All of the antibodies tested bound to gp120 
(Table 3). 
0183 The site of antibody binding on the HIV spike was 
mapped using mutant proteins that interfere with either the 
CD4bs (gp120(D368R)), or the CD4-induced co-receptor 
binding site (CD4i, gp120(I420R)). As reported, X. Wu et al., 
Science 329,856 (Aug. 13, 2010), VRC01 is classified as a 
CD4bs antibody since it is sensitive to the D368R mutation, 
but because of the proximity of the CD4i site, it also shows 
some sensitivity to the 1420R mutation. NIH45-46, which is 
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a VRCO1 variant, and antibodies 3BNC60, 8ANC 131, and 
12A12 showed ELISA patterns that were similar to VRC01 
(These clonal members were selected based on neutralizing 
activity, Table 3). Other clones, including 1B2530, and 
8ANC 195, were equally sensitive to both mutations and 
could not be classified precisely based solely on ELISA. 
0184. To determine whether the antibodies are polyreac 
tive, ELISAs were performed on purified ssDNA, dsDNA, 
insulin, and LPS. 63% of the anti-2CC Coreantibodies tested 
were polyreactive. It was concluded that the majority of the 
antibodies captured by the 2CC-bait recognize either the 
CD4bs or the CD4i site on gp120 and many are also polyre 
active. 
Example 4 
Somatic Hypermutation 
0185. Somatic hypermutation is required for development 
of high affinity antigenbinding and in Some cases contributes 
to polyreactivity of anti-HIV antibodies. To test if this is the 
case for highly mutated 2CC-core specific antibodies, 4 rep 
resentative antibodies were reverted to the corresponding ger 
mline. Reversion led to complete loss of antigen binding in 
ELISA for all 4 clones tested and to loss of polyreactivity. 
Example 5 
HIV Neutralization 
0186 HIV neutralizing activity was measured instandard 
ized in vitro assays using an initial panel of 8 viruses includ 
ing 3 tier 1 Clade A, B and C, and 5 tier 2 Clade B Env 
pseudovirus variants (M. S. Seaman et al., J. Virol 84, 1439 
(February, 2010)). The neutralizing activity of the antibodies 
was compared to VRC01 and purified serum IgG from the 
donors (FIG. 1A, Table 4 and FIG. 6). Antibodies showing 
high levels of neutralizing activity were further tested on a 
panel of 15 additional tier 2 Clade A, B, C, D, G, AG and AE 
Env pseudovirus variants (FIG. 1B, Table 5) including 5 
viruses that are resistant to VRCO1 (FIG. 1B and Table 5). 
0187 90% of all of the antibodies tested showed some 
neutralizing activity and 6 clones contained antibody variants 
that showed high levels of potency and breadth (FIGS. 1A, B 
and C and Tables 4 and 5). These clones were also the most 
abundant among those captured by the 2CC-bait in each of the 
four patients studied (Table 3). The most impressive of the 
new antibodies, 3BNC 117 belonging to a clone with 76 mem 
bers, showed an average ICso on a combined group of 14 tier 
2 viruses of 0.5ug/ml as compared to 1.8 g/ml for VRCO1 
(FIG. 1C, Tables 4 and 5). 
0188 Only 4 of the 20 viruses tested were more sensitive 
to VRC01 than 3BNC 117, whereas 14 were more sensitive to 
3BNC117 including DU172.17 which is completely resistant 
to VRC01 but sensitive to 3BNC117 (FIGS. 1B and C). 
NIH45-46, a new variant of VRCO1, is more potent than 
VRC01 on 15 of the 20 viruses tested but still less potent than 
3BNC117 (FIGS. 1B and C and Tables 4, and 5). 
0189 There was substantial variation in neutralizing 
breadth and potency among the members of the 5 most potent 
neutralizing antibody clones. For example, 3BNC 156, a vari 
ant of 3BNC117, neutralized only 2 of the viruses in the initial 
panel and at much higher concentrations than 3BNC117 
(FIG. 1A and Table 4) and 3BNC55, another variant, was 
intermediate between the two showing activity against 6 
viruses at an average ICso of 4 ug/ml (FIG. 1 and Table 4). 
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Finally, the most active antibodies were highly hypermutated. 
The average number of mutations for the top 10 antibodies 
was 72 for V and 45 for V, and this was associated with their 
breadth and potency (Tables 4 and 5). Reversion of the 
mutated residues to germline resulted in a complete loss of 
neutralizing activity for all of the antibodies tested. 
Example 6 
Identification of Diagnostic Peptides 
0190. The foregoing cloning strategy captured antibodies 
produced by antigenbinding memory B cells, but circulating 
antibodies are not produced by these cells, and originate 
instead from plasma cells in the bone marrow. However, 
cognate antigen cannot be used as bait to capture plasma cells 
because they do not express Surface Ig A. (Radbruch et al., 
Nat Rev Immunol 6, 741 (October, 2006)). In addition, the 
relationship between plasma cells in the bone marrow and 
circulating memory B cells is not defined precisely. To deter 
mine whether the antibodies cloned from memory B cells are 
also found in the bone marrow plasma cell compartment, 
CD138-expressing plasma cells were purified from paired 
bone marrow samples from 2 of the 4 individuals studied and 
used PCR to specifically amplify IgV genes for the more 
potent antibodies cloned from memory B cells in these indi 
viduals. The following were the clone specific primers for 
RUO1: 
(FWRD) 
(SEQ ID NO. 584) 
CTGCAACCGGTGTACATTCTCAAGTGCAACTGGTGC, 
(FWRD) 
(SEO ID NO. 585) 
CTGCAACCGGTGTACATTCTCAGGTCCATTTGTCACAG, 
(REV) 
(SEO ID NO. 586) 
TGCGAAGTCGACGCTGACGAGACAGTGACCTGC, 
(REV) 
(SEO ID NO. 587) 
TGCGAAGTCGACGCTGAAGAGACAATAATTTG, 
(REV) 
(SEO ID NO. 588) 
TGCGAAGTCGACGCTGACGAGACAATAACT 
and for RU1O : 
(FWRD) 
(SEO ID NO. 589) 
CTGCAACCGGTGTACATTTTCAGGGGCACTTGGTG, 
(REV) 
(SEO ID NO. 590) 
TGCGAAGTCGACGCTGAGGTGACGATGACCGTG. 
Members of the selected clones and large numbers of addi 
tional variants were readily identified in both patients. 
0191 To verify that these antibodies can also be found in 
serum, IgG purified from the serum of the same 2 and one 
additional individual were adsorbed on the 2CC-core bait and 
mass spectrometry was performed on the eluted IgG (FIG. 
1D, FIG. 7 and FIGS. 10A-C). Diagnostic peptides were 
found for the highly active antibody variants in all cases (FIG. 
7, FIG. 10A-C). It was concluded that broad and potent anti 
HIV antibodies cloned from memory B cells were also found 
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in the bone marrow plasma cell compartment, and in the 
circulating IgGs of patients with high serum titers of broadly 
neutralizing antibodies. 
Example 7 
HIV Antibody Binding Characteristics 
0.192 To determine whether antibody affinity to gp120 is 
related to neutralizing activity, the binding of the highly 
active antibodies, selected clonal relatives and germline 
reverted progenitors were compared using Surface Plasmon 
Resonance (SPR) (FIGS. 2A and B, FIG. 8 and Table 6). 
0193 The top neutralizing antibodies showed affinities (K) ranging from s 107-10' (M) on YU2 gp140 trimers 
and s 107-10' (M'.) on the 2CC-core (FIGS. 2A and B and 
Table 6). Consistent with their decreased neutralizing 
potency and breadth, 3BNC66, 3BNC156 and 3BNC55 dis 
played lower affinities on YU2 gp140 trimers than 3BNC117. 
but surprisingly, affinities to 2CC-core did not correlate with 
neutralizing activity (FIG. 1, FIG. 8, Table 4 and Table 6). 
Binding by SPR was not detected for any of the germline 
reverted antibodies tested (FIG. 2B. Table 6). It was con 
cluded that the anti-HIV antibodies captured by the YU2 
2CC-core tended to show higher affinity to the corresponding 
gp140 trimer than to the 2CC-core. 
(0194 When VRC01 binds to the HIV spike it produces 
large conformational changes that mimic CD4 binding and 
expose the CD4i site. By contrast, b12 and most other known 
anti-CD4bs antibodies do not. 
(0195 To determine whether this is a shared feature of the 
highly active antibodies, HIV-BAL.26Ac or -YU2 gp160Ac 
was expressed on the surface of HEK 293T cells and CD4i 
antibody binding measured in the presence or absence of CD4 
or anti-CD4bs antibodies (FIG. 2C). With one exception, all 
of the highly active antibodies tested resembled CD4 and 
VRCO1 in that they facilitated anti-CD4i antibody binding to 
either HIV-BAL.26 or YU2 gp160Ac or both (FIG. 2C). 
0196. The only highly active antibody that did not share 
this characteristic, 8ANC 195, was not a traditional anti 
CD4bs antibody in that it was equally sensitive to the D368R 
and I420R mutations (Table 3). In addition, it differed from 
the other highly active antibodies in its neutralization pattern: 
it did not neutralize any of the tier 1 viruses and showed potent 
activity against H086.8, a Glade B virus resistant to all other 
antibodies tested including 3BNC117, VRC01 and b12 
(FIGS. 1A and B and Tables 4 and 5). 
Example 8 
HIV Antibody Sequence Identity 
(0197) To determine whether highly active anti-CD4bs 
antibodies share common sequence features, the 10 best anti 
bodies: 2 variants each from 5 independently derived anti 
body clones from 5 different patients were aligned (FIG. 3). 
Comparison of the IgV regions revealed a highly conserved 
consensus sequence covering 68 IgV residues (FIG. 3A). 
The IgV consensus included 6 of VRC01-gp120 contact 
residues, including VRC01-Arg 71, which mimics the key 
interaction of Arg59, and Asp3682 (FIG. 3A). More 
over, the consensus, including the 6 contact residues, was 
entirely conserved in both of the closely related germline 
IgV genes (V1-2 and V1-46) that give rise to all of the 
antibodies in this class (FIGS. 3A and B). 
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0198 The codons encoding the consensus residues were 
highly somatically mutated in the 10 selected antibodies, 
nevertheless the amino acid sequence was conserved (FIG. 
9). The ratio of replacement to silent mutations in the con 
sensus residues ranged from 0.7-1.7, whereas it was 3.5-22 in 
the non-consensus residues indicating that conservation of 
the consensus is strongly selected (Table 7). In contrast to the 
heavy chain, the light chain of VRC01 made only 8 out of a 
total of 32 contacts with gp120. Consistent with its more 
limited role, comparison of the light chain sequences of the 
same antibodies uncovered a less extensive consensus cover 
ing 53 IgV, residues including 3 VRC01-gp120 contact resi 
dues (FIG.3B). Finally, like the heavy chains, the light chains 
arose from a limited set of germline genes: 2 were derived 
from Igk1D-33, 2 from Igk3-11, and one from Ig|L1-47 
(FIG. 3B and Table 3). Antibody 8ANC195, which differed 
from the others in several important respects did not entirely 
conform to the consensus and did notarise from related heavy 
or light chains (FIGS. 3A and B) It was concluded that there 
is significant sequence convergence among highly active ago 
nistic anti-CD4bs antibodies (HAADs). 
Example 9 
Crystal Structure of 3BNC60 Fab 
(0199 To determine whether the structure of the antibodies 
in different patients is also conserved, the crystal structure of 
the 3BNC60 Fab was solved to 2.65 A resolution and com 
pared it to VRC01.. The structure revealed the four domains, 
V, C1, V, and C., of a canonical Fab and the complemen 
tarity-determining regions (CDRs) within V, and V, that 
form the antigen binding site. The two Fabs in the 3BNC60 
asymmetric unit were almost identical; however, the confor 
mation of residues 74-78 in the loop connecting strands Dand 
E varied slightly due to different chemical environments 
formed by crystal lattice contacts. 
0200 Superimposition of the V. domains from 3BNC60 
and VRCO1 in the VRC01-gp120 co-crystal structure (T. 
Zhou et al., Science 329, 811 (Aug. 13, 2010)) yielded a root 
mean square deviation (rmsd) of 1.3 A (calculated for 111 Co. 
atoms) with major differences confined to CDR2 residues 
58-65 (3BNC60 numbering). Superimposing the structures 
indicated conservation of the recognition interface with 
gp120. For example, Arg72.svgo adopted a similar confor 
mation as Arg71 to, which mimics an important Salt bridge 
normally formed between Arg59, and Asp36820. In 
addition, Trp47so adopted the same conformation as 
Trp47, a residue that contacts gp120 and is involved 
with a complex network of interactions of aromatic and ali 
phatic residues that stabilize the conformations of CDRH3 
and CDRL3. Glnó5-yeo, which corresponds to 
Glné4, is within the residue segment (residues 58-65) 
that differs in structure from VRC01.. The conformation of 
this region of 3BNC60, which is involved in a lattice contact 
in the crystals, is likely to change upon binding gp120, as it 
would clash with the CD4-binding loop on gp120. 
0201 Superimposing the 3BNC60 and VRC01 V, 
domains yielded an rmsd of 0.9 A (calculated for 95 Co. 
atoms) and showed that some of gp120-contacting residues 
are structurally conserved; TyrSlavco and Glu91a-voo 
adopted similar conformations as Tyr91 to and 
Glu96, which engaged loop D of gp120 via polar inter 
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actions. Overall, these structural comparisons suggested that 
3BNC60 binds gp120 with the same architecture as observed 
for the binding of VRC01. 
Example 10 
HIV Antibody Consensus Sequence 
0202 The foregoing experiments defined a class of ago 
nistic anti-CD4bs antibodies, HAADs, that shares IgV and 
IgV consensus sequences including 8 of the contact residues 
between VRC01 and the HIV spike (FIGS. 3A and B). In five 
different donors, selected for their high level serologic anti 
HIV activity, these antibodies originated from only 2 closely 
Seq ID 
No. Antibody 
5 8A253HC 
6 8A275HC 
7 8ABM11 
8 8ABM12 
9 8ABMI13 
O 8ABM14 
1. 8ABM2O 
2 8ABM24 
3 8ABM26 
4. 8ABM27 
5 8ANC1 OSHC 
7 8ANC127HC 
8 8ANC131.HC 
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related IgV and 3 IgV, germline genes that conform to the 
HAAD consensus: V1-2 and V1-46 differ by only 7 amino 
acids, none of which are part of the consensus (FIG. 3A). 
Despite extensive Somatic hypermutation, the consensus resi 
dues were retained in their germline form. 
0203 The only exception to the consensus, 8ANC 195, 
differed from the others in a number of ways that suggest that 
it may have a unique mode of antigen recognition: absence of 
the Arg in the heavy chain that mimics the critical Arg59. 
and Asp368 120 contact site: unique neutralizing pattern; 
and inability to facilitate anti-CD4i antibody binding. This 
antibody is one of two distinct highly active antibodies arising 
in one patient, lending additional Support to the idea that 
serologic neutralizing activity is combinatorial. 
TABL E A 
Heavy Chain Amino Acid Sequence 
OGOLVOSGGGLKKPGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTAYNFODRLSLRRDRSTGTVFMELRGLRPDDT 
AVYYCARDGLGEVAPDYRYGIDWWGOGSTWIVTAASTKG 
OGLLVOSGGGVKKLGTSVTISCLASEYTFNEFVIHWIROAPGQGPL 
WLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSASTKG 
FOGHLVOSGGGVKKPGTSVTLSCLASEYTFTEFTIHWIROAPGOG 
PLWLGLIKRSGRLMTSYRFODRLSLRRDRSTGTVFMELRSLRTDD 
TAVYYCARDGLGELAPAYHYGIDAWGOGTTWIVTSASTS 
OGHLVOSGGGVKKLGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSAST 
OGHLVOSGGGVKKLGTSVTISCLASEDTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSASTS 
GHLVOSGGGXKKPGTSVTISCLASEYTFTEFTIHRIROAPGOGPL 
WLGLIKGSGRLMTSYGFODRLSLRRDRSTGTVFMELRSLRTDDTA 
WYYCARDGLGELAPAYHYGIDWWGOGTTWIWTSASTS 
GVHFOGHLVOSGGGVKKPGSSVTISCLASEYTFTEFTIHWIROAP 
GOGPLWLGLIKRSGRLMTSYRFODRLSLRRDRSTGTVFMELRGL 
RIDDTAVYYCARDGLGEVAPAYLYGIDWWGOGTTWIWTSASTS 
FOGOLVOSGGGVKKPGSSVTISCLASEYTFTEFTIHWIROAPGOG 
PLWLGLIKRSGRLMTSYGFODRLSWRRDRSTGTVFMELRSLRTDD 
TAVYYCARDGLGELAPAYHYGIDWWGOGTTWIVTSASTS 
OGOLVOSGGGVKKLGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSASTS 
OGHLVOSGXEVKKPGSSVKVSCKASGGTFSXYAIGWVROAPGO 
GLEWMGGIIPILGTTNYAORFOGGVTITADESTNTAYMDWSSLRSD 
DTAVYYCAKAPYRPRGSGNYYYAMDWWGOGTTWIVSSASTS 
OGHLVOSGGGVKKLGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSASTKG 
OGOLVOSGGGVKKLGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTVIVSSASTKG 
OGHLVOSGGGVKKLGTSVTISCLVSEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTSYOFODRLSLRRDRSTGTVFMELRGLRVDDT 
AVYYCARDGLGEVAPAYLYGIDAWGOGTTWIVTSASTKG 
OGOLVOSGGGLKKPGTSVTISCLASEYTFNEFVIHWIROAPGQGP 
LWLGLIKRSGRLMTAYNFODRLRLRRDRSTGTVFMELRGLRPDDT 
AVYYCARDGLGEVAPDYRYGIDWWGOGSTWIVTAASTKG 






















































